P3 - Poster Session 3

Event Time:	Tuesday May 7, 2019 11:30 am to 6:30 pm
Topic(s):	Neuro Trauma, Critical Care, and Sports Neurology, General Neurology, Aging, Dementia, Cognitive, and Behavioral Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), Headache, Movement Disorders, MS and CNS Inflammatory Disease, Neuromuscular and Clinical Neurophysiology (EMG), Neuro-oncology, Sleep
Director(s):
Description:
Completion Message:
CME Credits:	0
Core Competencies:

Program Speakers - Tentative
Start/End Time	Title	Faculty
Currently there are no events in the timeline.

Disclosures
Speaker	Disclosure

Abstract Presenters
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	001	Repetitive transcranial magnetic stimulation with H coil in Progressive Supranuclear Palsy: a double-blind, placebo-controlled, crossover study	Disclosure: Dr. Fichera has nothing to disclose.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	001	Unusual Quivering Muscle	Disclosure: Dr. Mahuwala has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	001	Impact of Migraine Headache Day Frequency on Associated Health : Results from the 2017 Migraine in America Symptoms and Treatment (MAST) Study	Disclosure: Dr. Schwedt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Cipla, Dr. Reddy’s Laboratories, Eli Lilly, Ipsen Bioscience, Novartis, Salvia, Teva, and XoC Pharmaceuticals. Dr. Schwedt has received personal compensation in an editorial capacity for Associate Editor for Headache and Cephalalgia journals. Dr. Schwedt has received compensation for serving on the Board of Directors of Aural Analytics and Nocira. Dr. Schwedt has received research support from Amgen.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	001	Utility of the FTLD-CDR in the mild FTLD: Data from the ARTFL/LEFFTDS Consortium	Disclosure: Dr. Miyagawa has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	001	Predictors of Processing Speed Test Performance in a Large Multiple Sclerosis Population	Disclosure: Dr. Conway has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arena pharmaceuticals. Dr. Conway has received personal compensation in an editorial capacity for Neurotherapeutics. Dr. Conway has received research support from Novartis Pharmaceuticals.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	001	Design and Implementation of a Multidisciplinary Integrated Stroke Prevention Clinic	Disclosure: Dr. Kim has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	001	Application of electrical impedance myography (EIM) as a potential biomarker of Inclusion Body Myositis (IBM): A pilot study	Disclosure: Dr. Roy has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	001	Safety and Efficacy of Adjunctive Perampanel in Pediatric Patients (Aged 4 to ?12 Years) with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Final Results from the 311 Core Study	Disclosure: Dr. Flamini has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai and Lundbeck. Dr. Flamini has received research support from GW.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	001	Radiation-Induced Neuropathy - a Late Effect of Cancer Therapy	Disclosure: Dr. Grisold has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	001	Performance and Yield of MRI in Patients with Deep Intracerebral Hemorrhage	Disclosure: Dr. Moretti has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	002	Evaluation and Management of Sleep-related Disorders in a Multidisciplinary Multiple System Atrophy Clinic	Disclosure: Dr. Devine has nothing to disclose.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	002	Nerve Action Potential Analysis Versus Biopsies in Small Fiber Polyneuropathy	Disclosure: Dr. Parry has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	002	Feasibility and Acceptability of Smartphone Based Migraine Behavioral Therapy in the Neurology Clinic: A Single Arm Study	Disclosure: Dr. Minen has nothing to disclose.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	002	Characterization of language features of subtypes of primary progressive aphasia based on clustering analysis of brain metabolism	Disclosure: Dr. Matias-Guiu has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	002	A Natural Language Algorithm Identifies Multiple Sclerosis Relapses from Clinical Notes With High Sensitivity	Disclosure: Dr. Krishnakumar has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	002	Sleep Disordered Breathing (SDB) - An Overlooked Modifiable Risk Factor in Acute Stroke Care	Disclosure: Dr. Gudlavalleti has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	002	Serologic and Pathologic Correlation in Idiopathic Inflammatory Myopathies: A Retrospective Chart Review	Disclosure: Dr. Ortiz-Guerrero has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	002	Risk of Hospitalization in Patients With Uncontrolled Epilepsy Treated with a Long Versus Short Half-Life Adjunctive Antiepileptic Medication	Disclosure: Dr. Cramer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB, Sunovion, Supernus, Sun, Liva-Nova, Eisai, Inc.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	002	Sequelae of Cranial Irradiation: Stroke-like Migraine Attacks After Radiation Therapy (SMART) Syndrome	Disclosure: Dr. Hamouda has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	002	Prevalence and Impact of Systemic Inflammatory Response in Acute Intracerebral Hemorrhage	Disclosure: Dr. Kaplan has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	003	Incidence and trends of Progressive Supranuclear Palsy and Corticobasal Syndrome in Olmsted County: a population based study (1995-2005).	Disclosure: Dr. Stang has nothing to disclose.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	003	A pilot trial of alternate day deflazacort in Becker muscular dystrophy	Disclosure: Dr. Marozzo has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	003	Assessing Unmet Treatment Needs and Associated Disability in Persons With Migraine: Results from Migraine in America Symptoms and Treatment (MAST) Study	Disclosure: Dr. Reed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Eli Lilly and Promius/Dr Reddy's Labs. Dr. Reed has received research support from Allergan, Promius/Dr. Reddy's Labs.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	003	Neuropsychiatric Symptoms and the Ultimate Game in Frontotemporal Dementia Compared to Alzheimer's Disease	Disclosure: Dr. Yerokhin has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	003	myMS; A Comprehensive Patient-Centered Mobile App to Monitor MS at Home	Disclosure: Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	003	Pharmacological Smoking Cessation Therapies for Patients with Cerebrovascular Disease: a Systematic Review	Disclosure: Dr. Parikh has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	003	Willingness to Participate in Natural History Studies amongst Patients with Sporadic Inclusion Body Myositis (sIBM): A Comparison Between the United States and Australia	Disclosure: Dr. Mathew has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis Pharmaceuticals, Inc.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	003	Cross-sensitivity of behavioral adverse effects of perampanel and levetiracetam.	Disclosure: Dr. Tolba has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	003	Atypical Non-Enhancing Primary Central Nervous System Lymphoma	Disclosure: Dr. Valenti has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	003	The Use and Yield of Vascular Imaging in Patients with Deep Intracerebral Hemorrhage	Disclosure: Dr. Moretti has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	004	Impact of Supine Hypertension in Target Organ Damage and Mortality in Patients with Neurodegenerative Synucleinopathies	Disclosure: Dr. Palma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck and Biogen. Dr. Palma has received personal compensation in an editorial capacity for Clinical Autonomic Research.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	004	Cognitive Abnormalities In DM1: A Five Years Longitudinal Study	Disclosure: Dr. Angelini has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	004	The Italian chROnic migraiNe (IRON) Registry: a report from the first 340 patients	Disclosure: Dr. Barbanti has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with electroCore, LLC, Eli Lilly, Lusofarmaco, MSD, Novartis, Teva, and Visupharma.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	004	Getting Granular with Progranulin: Abnormal Eating in FTLD+GRN	Disclosure: Dr. McCollum has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	004	Automated gait analysis using wearable sensors can detect objective and reliable quantification of disability in people with Multiple Sclerosis	Disclosure: Dr. AngelinI has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	004	Improving Stroke Education in Spanish-Speaking Patients	Disclosure: Dr. Nguyen has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	004	A Case of Pembrolizumab-Induced Autoimmune Necrotizing Myopathy	Disclosure: Dr. Chen has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	004	Characteristics of Interventional Epilepsy Clinical Trials During the Last Decade	Disclosure: Dr. Eslami has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	004	Primary Diffuse Leptomeningeal Gliomatosis, a Rare Mimic of Tuberculous Meningitis	Disclosure: Dr. Lobbous has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	004	Use and Complications of Pharmacologic VTE Prophylaxis in Intracerebral Hemorrhage Patients	Disclosure: Dr. Zurasky has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	005	Prevalence estimates and clinical characterization for tremor and dystonia in Progressive Supranuclear Palsy	Disclosure: Dr. Wagle-Shukla has nothing to disclose.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	005	Non-coding repeats in the ATXN8OS gene are expanded in Japanese patients with amyotrophic lateral sclerosis	Disclosure: Dr. Hirano has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Daiichi Sankyo, Eisai, Otsuka Pharma, Sanofi, Shire.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	005	Development and Validation of the Migraine Knowledge Assessment Tool—MigKAT-12©	Disclosure: Dr. Gordon has nothing to disclose.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	005	Clinical Swallowing Profile of Patients with Frontotemporal Dementia	Disclosure: Dr. Iacolucci has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	005	Identifying SPMS: Are U.S. Neurologists Aligned on the Most Influential Disease and Patient Metrics?	Disclosure: Dr. Naismith has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Alkermes, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, TG Therapeutics, Viela Bio. Dr. Naismith has received personal compensation in an editorial capacity for NEJM Journal Watch.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	005	Motivation for Behavioral Change for Weight Loss in Obese Patients with Acute Stroke or TIA	Disclosure: Dr. Orgass has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	005	Prevalence and Characterization of Pain as a Symptom Amongst Sporadic Inclusion Body Myositis (sIBM) Patients	Disclosure: Dr. Said-Said has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	005	Perampanel Use in Established, Refractory, and Super-Refractory Status Epilepticus (SE): a Summary of Cases from Austria, Finland, Germany, and Spain	Disclosure: Dr. Strzelczyk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Desitin, UCB Pharma, Zogenix. Dr. Strzelczyk has received research support from UCB Pharma, Zogenix.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	005	Rare Presentation of CLL as Expansile Spinal Cord Lesions: ?A Radiographic Chronicle of Treatment Response	Disclosure: Dr. Cheung has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	005	Outcomes with Reversal of Vitamin K Antagonist-Associated Intracerebral Hemorrhage	Disclosure: Dr. Breit has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	006	Video research visits for atypical parkinsonian syndromes among Fox Trial Finder participants	Disclosure: Dr. Tarolli has nothing to disclose.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	006	Electrodiagnostic elucidation of a novel variant in the acetylcholine receptor gene identified by rapid trio exome sequencing, leading to the diagnosis and treatment of congenital myasthenia syndrome in an infant presenting with fetal akinesia deformation sequence.	Disclosure: Dr. Schwarz has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	006	Provider Preference for Acute Migraine Treatment in the Emergency Room: A Professional Practice Gap	Disclosure: Dr. Huang has nothing to disclose.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	006	Prominent Auditory Hallucinations in Behavioral Variant Frontotemporal Dementia Associated with a MAPT Mutation	Disclosure: Dr. Widmeyer has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	006	Constructing a Molecular Model of Disease Severity in Multiple Sclerosis	Disclosure: Dr. Barbour has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	006	Geographic Proximity to Healthy Food is Not Independently Associated with Ischemic Stroke Risk Factors	Disclosure: Dr. Howard has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	006	Necrotizing Autoimmune Myopathy Associated with Tubular Aggregates	Disclosure: Dr. Madigan has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	006	Expert Opinion: A New Treatment Algorithm for Lennox-Gastaut Syndrome (LGS) in Adult Patients	Disclosure: Dr. Kothare has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	006	Latent Radiation-Induced Cerebral Vasculopathy	Disclosure: Dr. O'Mara has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	006	Cerebral Small Vessel Disease Markers and Their Relation to Hematoma Volume, Expansion and Functional Outcome	Disclosure: Dr. Warrier has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	007	The Diagnostic Journey of Patients with Progressive Supranuclear Palsy (PSP) in US Electronic Health Record Data	Disclosure: Dr. Viscidi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	007	Reinnervation in Face Transplantation: The Role of Electromyography	Disclosure: Dr. Hasan has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	007	Investigating the Role of Artmaking as a Therapeutic Tool in the Treatment of Chronic Migraine	Disclosure: Dr. Simon has nothing to disclose.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	007	Motor Features In Familial Frontotemporal Dementia due to MAPT, GRN or C9orf72 mutations	Disclosure: Dr. Deutschlander has received research support from Allergan, Inc..
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	007	Manual Dexterity Test is a Better Predictor of Disability than Walking Speed in Multiple Sclerosis: A Large Outpatient Analysis	Disclosure: Dr. Khan has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	007	Abdominal Obesity is a Risk Factor for Ischaemic Stroke	Disclosure: Dr. Rahman has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	007	HIV-associated Myositis and Response to Immune Therapy	Disclosure: Dr. Samudra has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	007	Effect of Concomitant Enzyme-Inducing Antiepileptic Drugs (EIAEDs) on the Safety and Efficacy of Adjunctive Perampanel in Patients Aged 4 to ?12 years with Partial-Onset Seizures (POS): Final Results from the 311 Core Study	Disclosure: Dr. Milh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Shire, Novartis, Livanova and GW Pharma.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	007	Multinodular and Vacuolating Neuronal Tumor - Are We Only Seeing the Tip of the Iceberg?	Disclosure: Dr. Huang has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	007	Treatment Outcomes of Primary Endovascular Embolization in Patients Randomized in Unruptured Arteriovenous Malformations with a Subgroup Analysis of ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations)	Disclosure: Dr. Sahito has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	008	Symptoms of Levodopa Intolerance During Acute Levodopa Challenge Test: Predictor of MSA in Early Years of Parkinsonism	Disclosure: Dr. Acharya has nothing to disclose.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	008	Concentric Needle Voluntary Jitter Assessment in Patients with Mitochondrial Myopathy.	Disclosure: Dr. Caldas has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	008	Incidence of Pregnancy Related Migraine Headache During Pregnancy and Post-Partum and Associated Comorbidities: An Update from a Nationwide Inpatient Sample Database	Disclosure: Dr. Myers has nothing to disclose.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	008	Characterization of Sequence Variants in Downstream Flanking Region of C9orf72 Hexanucleotide Repeat in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis	Disclosure: Dr. Grando has received research support from Asuragen.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	008	Mobilizing a Digital Research Ecosystem for Multiple Sclerosis Research and Care	Disclosure: Dr. Hartsell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	008	Association between albuminuria and the risk of stroke: a secondary analysis of the SPRINT trial	Disclosure: Dr. Soares Dos Reis has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	008	Pembrolizumab Induced Myositis	Disclosure: Dr. Elkhider has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	008	Pharmaceutical Evaluation And Therapeutic Drug Monitoring Of Levetiracetam In Patients With Epilepsy	Disclosure: Dr. Hernandez Mitre has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	008	WHO grade I meningioma with simultaneous pulmonary metastasis: a rare presentation	Disclosure: Dr. Chaudhry has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	008	A Tertiary Care Center’s Experience with Andexanet Alfa for Reversal of Factor Xa Inhibitor Associated Intracranial Hemorrhage	Disclosure: Dr. Smith has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	009	A Clinical Staging System and Convenient Prognostic Tool for Progressive Supranuclear Palsy	Disclosure: Dr. Golbe has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BMS, AbbVie, and USB. Dr. Golbe has received royalty, license fees, or contractual rights payments from Rutgers University.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	009	EMG, MEP, and SSEP in the Intraoperative Neurophysiologic Monitoring of Lumbar Surgeries	Disclosure: Dr. Nguyen has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	009	Cognitive Dysfunction in Chronic Migraine	Disclosure: Dr. Butt has nothing to disclose.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	009	Frontotemporal Lobar Degeneration in the Differential Diagnosis of the Oldest-Old	Disclosure: Dr. Embree has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	009	LIFEware Life Satisfaction and Pessimism are Correlated with the Beck Depression Inventory-Fast Screen and with Disability Progression in Individuals with Multiple Sclerosis	Disclosure: Dr. Weinstock-Guttman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, EMD Serono, Genentech, Novartis, Mallinckrodt, and Celgene. Dr. Weinstock-Guttman has received research support from Biogen Idec, Novartis, and Genentech.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	009	Correlation of Different Sleep Apnea Scores with Polysomnographic Study in Patients with Acute Stroke and Transient Ischemic Attack	Disclosure: Dr. Patel has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	009	Genetic Testing - Muddying the Water for Diagnosis of Inflammatory Myopathies	Disclosure: Dr. Van De Rijn has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	009	Pharmacokinetic Study of Valtoco™ (NRL-1; diazepam nasal spray) in Patients with Epilepsy Under Ictal and Inter-ictal Conditions – Interim Report	Disclosure: Dr. Hogan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Neurelis. Dr. Hogan has received research support from UCB Pharmaceuticals, Neurelis Pharnaceuticals, Biogen Inc., Engage Therapeutics.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	009	Ischemic Stroke After CAR-T Cell Therapy	Disclosure: Dr. Shah has nothing to disclose.
Neurocritical Care: Intracerebral Hemorrhage and Brain Arteriovenous Malformations
Start Time	Pub.	Title	Presenter
11:30 AM	009	Comparison of Intervention with Medical Treatment if Young Patients with Unruptured Brain Arteriovenous Malformation	Disclosure: Dr. Saeed has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	010	Wide distribution of alpha-synuclein oligomers in multiple system atrophy brain detected by proximity ligation	Disclosure: Dr. Sekiya has nothing to disclose.
Neuromuscular and Clinical Neurophysiology (EMG) ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	010	Patient Reported Quality of Life Measures in Limb-Girdle Muscular Dystrophy: Correlation with Clinical Outcomes	Disclosure: Dr. Duong has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Roche Scholar Rock Novartis Solid Bio ATOM International.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	010	High Prevalence of Rape and Sexual Abuse among Chronic and Refractory Migraine Patients	Disclosure: Dr. Oterino Duran has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Almirall, Merck Serono, TEVA, Sanofi Genzyme, Allergan, MSD and Novartis. Dr. Oterino Duran has received research support from Sanofi Genzyme, Novartis.
Frontotemporal Dementia I
Start Time	Pub.	Title	Presenter
11:30 AM	010	Regionally Specific Variation in Brain Structure in Behavioral Variant Frontotemporal Dementia Compared to Alzheimer’s Dementia	Disclosure: Dr. Meysami has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	010	Screening for Cognitive Impairment in People with Multiple Sclerosis: Is A Unidimensional Measure Really Sufficient to Detect the Cognitive Elephant in the Room?	Disclosure: Dr. Gudesblatt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Novartis, Sanofi-Genzyme, and Teva Neuroscience. Dr. Gudesblatt has received research support from Acorda, Adamas, Biogen, Novartis, Roche, Sanofi-Genzyme, and Teva Neuroscience.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	010	A hospital’s perspective: economic evaluation of hospitalization vs rapid outpatient evaluation for TIA and minor strokes.	Disclosure: Dr. Shapiro has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	010	A Mixed Picture: Dermatomyositis with features of Necrotizing Myopathy	Disclosure: Dr. Ullah has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	010	Analysis of Hematological and Serum Chemistry Abnormalities in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures	Disclosure: Dr. Kotagal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with LivaNova, UCB Pharma, Eisai and Greenwich Biosciences.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	010	A case of Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR): a distinct genetic locus with an excellent outcome	Disclosure: Dr. Nemade has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	010	Early Prediction of Malignant Brain Edema After Ischemic Stroke: a Systematic Review and Meta-Analysis	Disclosure: Dr. Wu has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	011	Levodopa-induced dyskinesia in Atypical Parkinsonism: A population-based cohort study	Disclosure: Dr. Turcano has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	011	Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study Demonstrate a High Level of Unmet Need for Migraine Treatment in People Who Discontinue Acute Prescription Migraine Medication	Disclosure: Dr. Manack Adams has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Aubrey Manack Adams, and Allergan plc. Dr. Manack Adams holds stock and/or stock options in Aubrey Manack Adams, and Allergan plc which sponsored research in which Dr. Manack Adams was involved as an investigator. Dr. Manack Adams holds stock and/or stock options in Aubrey Manack Adams, and Allergan plc.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	011	Pilot study investigating the use of high frequency transcranial magnetic stimulation for primary progressive apraxia of speech	Disclosure: Dr. Shpiner has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	011	Validation of the Scoring Algorithm for a Novel Integrative Secondary Progressive Multiple Sclerosis (SPMS) Screening Tool	Disclosure: Dr. Ziemssen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Fees for participation in scientific advisory boards from Bayer Healthcare, Biogen Idec, Novartis, Merck Serono, Teva, Genzyme, and Synthon; Speaker honorarium from Bayer Healthcare, Biogen, Genzyme, Merck Sharp & Dohme, GlaxoSmithKline, Novartis, Teva, Sanofi, and Almirall. Dr. Ziemssen has received research support from Bayer Healthcare, Biogen, Genzyme, Novartis, Teva, and Sanofi.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	011	Alcohol-Related Hospital Encounters Trigger Stroke Events	Disclosure: Dr. Gentile has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	011	A Cross-Sectional Study of Inclusion Body Myositis: Novel Exam Findings for Early Screening and Detection, Correlation with Items in the Current Functional Rating Scale	Disclosure: Dr. Lin has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	011	Efficacy Extrapolation Analyses of Extended-Release Oxcarbazepine (Oxtellar XR®) as Once-Daily Monotherapy in Adults and Children with Partial-Onset Seizures	Disclosure: Dr. Mendes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Supernus Pharmaceuticals, Inc.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	011	A Case of Paraneoplastic Myasthenia Gravis as the Initial Presentation in a Patient with Non-Hodgkin’s Lymphoma	Disclosure: Dr. Cormier has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	011	Ischemic and Hemorrhagic Stroke in Native Americans	Disclosure: Dr. King has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	012	Distinct clinical features of predominant pre-synaptic and trans-synaptic nigrostriatal dysfunction in multiple system atrophy	Disclosure: Dr. Chung has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	012	How Often Do ED Patients Receive Opioids for the Treatment of Migraine?	Disclosure: Dr. Amin has nothing to disclose.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	012	Prosodic Stress: Acoustic Changes in Spoken English in Patients with Left and Right Hemisphere Lesions	Disclosure: Dr. Hollen has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	012	Clinical Evaluation of a Software Medical Device for the Self-Assessment of Patients Living with Multiple Sclerosis: Results of the MSCopilot Study	Disclosure: Dr. Maillart has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ad Scientiam, Biogen Idec, Genzyme, Novartis, Merck Serono, Roche, Sanofi, Teva Pharma. Dr. Maillart has received research support from Novartis, Roche.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	012	Association Between Recent Cannabis Use and Acute Ischemic Stroke	Disclosure: Dr. San Luis has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	012	A Case Series of Immune Checkpoint Inhibitor-Associated Peripheral Nervous System Complications	Disclosure: Dr. Muccilli has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	012	Dexamethasone is effective in treatment of infantile spasms (IS)	Disclosure: Dr. Gabriel has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	012	Co-occurrence of Follicular Lymphoma and CNS Intravascular Lymphoma in a patient with HIV/AIDS: A Case report	Disclosure: Dr. de Carvalho Cardozo Hernández has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	012	Reversible Cerebral Vasoconstriction Syndrome resulting from Tyramine-Rich diet while on Antidepressants	Disclosure: Dr. Sivakumar has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	013	Unique findings of susceptibility-weighted magnetic resonance (MR) imaging in multiple system atrophy (MSA): The differentiation of MSA from Parkinson’s disease (PD)	Disclosure: Dr. Arai has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	013	The Impact of Offering Monthly and Quarterly Dosing Options for a New Class of Migraine Preventive Therapy on Likelihood of Acceptance and Adherence in Adults With Migraine	Disclosure: Dr. Cowan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	013	Neuropsychological Similarities and Differences between Typical Amnestic Alzheimer’s Disease and Its Non-Amnestic Variants	Disclosure: Dr. Mendez has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	013	Deep Neural Net Forecasting of Multiple Sclerosis Disease Severity	Disclosure: Dr. Insley has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	013	Clinical Characteristics of Methamphetamine Associated Acute Ischemic Stroke	Disclosure: Dr. Walia has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	013	Ocular symptoms after immune checkpoint inhibitors.	Disclosure: Dr. Fotedar has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	013	Relationship Between Adverse Event Incidence and Eslicarbazepine Acetate (ESL) Dose Across Weight Groups in Clinical Trials of Adjunctive ESL in Children (Aged 4–17 Years) with Focal Seizures	Disclosure: Dr. Pina-Garza has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Sunovion Pharmaceuticals Inc. Supernus UCB Lundbeck Greenwich Pharmaceuticals Aquestive and Eisai.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	013	Use of Temozolamide in a Rare Case of Diffuse Leptomeningeal Glioneuronal Tumor	Disclosure: Dr. Montalvo Perero has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	013	Impact Of Doing Echocardiogram (ECHO) And Brain Magnetic Resonance Imaging (MRI) On Length Of Stay And Hospital Charges In Sschemic Stroke Patients In United States: Analysis of Nationwide Inpatient Sample (NIS) 2006-2014	Disclosure: Dr. Nguyen has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	014	Bradykinesia, Mitochondrial Myopathy and Progressive Ophthalmoplegia Associated with a Novel DNM1L Mutation	Disclosure: Dr. Parnes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Advisory committee or as a consultant for the Kadmon Corporation and Teva Neuroscience. Payment for contributions to Medlink.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	014	Serum Phosphate Levels in Patients with Migraine	Disclosure: Dr. Jung has nothing to disclose.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	014	Mapping the Neural Basis of Declarative Verbal Memory: Evidence from Mesial Temporal Lobe Lesions	Disclosure: Dr. Gleichgerrcht has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	014	Importance of Optical Coherence Tomography Angiography in Differential Diagnosis of NMOSD and RRMS	Disclosure: Dr. Tiftikcioglu has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	014	Cerebral Small Vessel Disease and Cervicocerebral Large Artery Stenosis Independently Increase Ischemic Stroke Risk in the General Population	Disclosure: Dr. Han has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	014	Dermatomyositis after Intralesional Immunotherapy for Warts	Disclosure: Dr. Anderson has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	014	First Canadian experience of brivaracetam in a highly difficult to treat epilepsy population: a two-center clinical study	Disclosure: Dr. Lafortune has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	014	Chemotherapy in Hemangioblastomatosis: A Case Report with Mutational Profiling and Literature Review	Disclosure: Dr. Zhang has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	014	The Role of Induced Hypertension and Hyperbaric Oxygen Therapy in Moyamoya Disease: A Case Report	Disclosure: Dr. Pabst has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	015	Expression change of plasma microRNAs in multiple system atrophy and Parkinson’s disease.	Disclosure: Dr. Uwatoko has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	015	Medical Cannabis for Chronic Migraine: A Retrospective Review	Disclosure: Dr. Mechtler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva, Promius, Allergan, Avanir, Amgen, Boston Biomedical, electroCore, Alder Biopharmaceuticals, Lilly. Dr. Mechtler has received research support from Dent Family Foundation.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	015	Incidental learning throughout life	Disclosure: Dr. Torres has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	015	Longitudinal study of retinal layer thinning and brain atrophy in clinically isolated syndrome and multiple sclerosis	Disclosure: Dr. Link has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	015	Trans Esophageal Echo in Transient Ischemic Attack	Disclosure: Dr. Navalkele has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	015	The Checkpoint Inhibitor Imperative: Differentiating neuromuscular complications	Disclosure: Dr. Prior has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	015	Medical Marijuana and Its Use in Treatment-Refractory Seizures: The Pittsburgh Experience	Disclosure: Dr. Sianati has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	015	Cardiac Arrest due to Autonomic Dysfunction in a Patient with Primary Spinal Cord Glioblastoma	Disclosure: Dr. Fan has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	015	Pupillometry as a predictor of outcome after hemicraniectomy	Disclosure: Dr. Mamdani has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	016	Pseudobulbar Affect in Parkinsonian Syndromes	Disclosure: Dr. Elkurd has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	016	Enhancing outpatient infusion with interdisciplinary care to manage refractory pediatric migraine: Preliminary outcomes from “CAMP” (the Comprehensive Aggressive Migraine Protocol)	Disclosure: Dr. Bickel has nothing to disclose.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	016	Accelerated Forgetting in Patients with Epileptic and Psychogenic Seizures	Disclosure: Dr. Tom has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	016	Validity and Potential Added Value of Multi-Domain Computerized Cognitive Assessment for Patients with Multiple Sclerosis	Disclosure: Dr. Golan has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	016	Stroke Code Quality Metrics and Functional outcomes: Advanced Practice Providers versus Neurology Residents	Disclosure: Dr. Khan has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	016	Familial Inclusion Body Myositis with Negative Anti-cytosolic 5'-nucleotidase 1A (cN1A) Antibody Test.	Disclosure: Dr. Khosa has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	016	Eslicarbazepine Acetate in Post-Stroke Epilepsy: A post-hoc Analysis from the Clinical Practice Study Euro-Esli	Disclosure: Dr. Sales has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	016	CNS non-germinomatous germ cell tumor causing obstructive hydrocephalus, Parinaud’s syndrome, and secondary Parkinsonism	Disclosure: Dr. Cole has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	016	Transcranial Doppler Emboli Monitoring in Patient with Left Ventricular Assistant Device: A Systematic Review of the Literature	Disclosure: Dr. Fan has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	017	Impact of REM Sleep Behavior Disorder on Orthostatic Hypotension in Multiple System Atrophy	Disclosure: Dr. Saitoh holds stock and/or stock options in Meiji Holdings Co., Ltd.. Dr. Saitoh has received research support from Novartis Pharma K.K..
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	017	Most Bothersome Associated Migraine Symptom: Results from 2017 Migraine in America Symptoms and Treatment (MAST) Study	Disclosure: Dr. Munjal has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Dr Reddy & Laboratories.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	017	A Case of Reversible Bilateral Hippocampal Injury Secondary to Benzodiazepine Abuse	Disclosure: Dr. Chu has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	017	A Novel Clinically-Feasible Balance Task Predicts Future Falls and Fall-Related Injuries Better Than Traditional Metrics in Early Multiple Sclerosis Patients	Disclosure: Dr. Brandstadter has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	017	Stroke Version 2.0 Common Data Element (CDE) Review: Updates to the National Institute of Neurological Disorders and Stroke (NINDS) CDEs for Stroke	Disclosure: Dr. Feldman has nothing to disclose.
Acquired Diseases of Muscle
Start Time	Pub.	Title	Presenter
11:30 AM	017	Amyloid Myopathy as an initial manifestation of Primary AL associated amyloidosis: A Case Report and review of literature.	Disclosure: Dr. Bhatia has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	017	Phase II, Open-Label Pharmacokinetic (PK) Study of Perampanel Oral Suspension as Adjunctive Therapy in Pediatric Patients (Aged =1 to <24 months) with Epilepsy: Study 238 Design and Preliminary Safety Data	Disclosure: Dr. Renfroe has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Livanova, Ipsen.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	017	A 43 year-old woman with primary central nervous system angiosarcoma with CIC-LEUTX gene rearrangement	Disclosure: Dr. Noch has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	017	Neurological Complications of Left Ventricular Assist Device	Disclosure: Dr. Bandaru has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	018	RT001 to treat neurodegeneration—Case Study: Improvement in a single patient with Late Onset Tay-Sachs Disease (LOTS)	Disclosure: Dr. Milner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Retrotpe. Dr. Milner has received compensation for serving on the Board of Directors of Retrotope, Espero Biopharma, Renexxion. Dr. Milner holds stock and/or stock options in Retrotope, Espero Biopharma, Renexxion which sponsored research in which Dr. Milner was involved as an investigator. Dr. Milner holds stock and/or stock options in Retrotope, Espero Biopharma, Renexxion.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	018	Obesity is Associated with Increased Odds of Hospitalization Following Emergent Care for Pediatric Migraine	Disclosure: Dr. Szperka has received research support from Pfizer.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	018	Serial-position effect as a biomarker in the diferential diagnosis of mild cognitive impairment. A multimodal biomarkers aproach.	Disclosure: Dr. Calandri has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	018	The Impact of Cognitive Testing on Disability Measurement during the Follow-up of People with Multiple Sclerosis	Disclosure: Dr. Sacca has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alrmirall, Biogen Idec, Forward Pharma, Merk, Mylan, Novartis, Pomona, Sanofi Genzyme, Roche, Teva.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	018	Impact of Residency Training Programs on Outcomes of Acute Ischemic Stroke	Disclosure: Dr. Patel has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	018	A Randomized Lifestyle Intervention Study Improves Mobility and Neuropathy in Diabetes	Disclosure: Dr. Zilliox has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	018	Inpatient Hospitalization Rates in Patients Diagnosed with Epilepsy and Treated with Perampanel or Lacosamide	Disclosure: Dr. Faught has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with As a KOL for Eisai inc.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	018	Optic Neuropathy Related to Esophageal Carcinoma	Disclosure: Dr. Sarangi has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	018	Neurologic Complications Associated with Veno-Venous ECMO: A Systematic Review	Disclosure: Dr. Rice has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	019	A Futility Trial of Sirolimus in Multiple System Atrophy: Protocol, Recruitment and Preliminary Adverse Event Profile	Disclosure: Dr. Palma has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck and Biogen. Dr. Palma has received personal compensation in an editorial capacity for Clinical Autonomic Research.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	019	Visual discomfort in migraine is evoked by both melanopsin and cone directed stimulation	Disclosure: Dr. Kaiser has received royalty, license fees, or contractual rights payments from Alder BioPharmaceuticals.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	019	Glutamate-weighted CEST (GluCEST) MRI contrast at the site of transcranial magnetic stimulation is related to changes in motor evoked potentials	Disclosure: Dr. Medaglia has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	019	Wearable sensors for evaluation gait disorder in MS estimated by Learning Entropy	Disclosure: Dr. Dostal has nothing to disclose.
Stroke Continuum of Care I: Stroke Prevention, Risk Factors and Quality Metrics
Start Time	Pub.	Title	Presenter
11:30 AM	019	Nutritional knowledge and counseling of stroke patients by neurology residents	Disclosure: Dr. Benameur has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	019	Driving Ability Correlated with Severity of Polyneuropathy	Disclosure: Dr. Lopez has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	019	Study 410 Enrollment Update: Multicenter, Open-Label, Phase IV Study of Perampanel as Monotherapy or First Adjunctive Therapy in Patients with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS)	Disclosure: Dr. Klein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Yes. Abbott: consultant; Alliance: medical advisory board; Acquestive: ad board; Eisai: consultant speaker; Lundbeck: research support; Sunovion: speaker; UCB Pharma: consultant, speaker.. Dr. Klein has received research support from Yes. Lundbeck.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	019	Glioblastoma with bilateral extraocular muscle infiltration	Disclosure: Dr. Ruff has nothing to disclose.
Neurocritical Care: Ischemic Stroke and Complications of Cardiocirculatory Support
Start Time	Pub.	Title	Presenter
11:30 AM	019	Neurologic Complications of HeartWare and HeartMate II	Disclosure: Dr. Zhang has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	020	An Unusual Case of Parkinsonism in a Young Woman, What Can It Be?	Disclosure: Dr. Caraballo-Cartagena has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	020	Trends in the Incidence of Migraine in Patients Hospitalized for Acute Ischemic Stroke in the United States Using the Nationwide Inpatient Sample Database	Disclosure: Dr. De Souza has nothing to disclose.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	020	A Visual World After Losing All Vision: The Preservation of Visual Imagery Following Complete Loss of Light Perception	Disclosure: Dr. Dietz has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	020	Retinal Damage in Multiple Sclerosis Disease Subtypes quantified by optical coherence tomography	Disclosure: Dr. hamza has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	020	Care giver burden among carers of young stroke survivors	Disclosure: Dr. Aghoram has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	020	Determinants of HIV-Associated Neuropathic Pain Using a Novel Instrument	Disclosure: Dr. Iyagba has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	020	Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Refractory Epilepsy	Disclosure: Dr. Barr has nothing to disclose.
The Power of Case Reporting in Neuro-Oncology II
Start Time	Pub.	Title	Presenter
11:30 AM	020	Primary peripheral neurolymphomatosis of the brachial plexus: a case report.	Disclosure: Dr. Salvadeeswaran has nothing to disclose.
Neurocritical Care: Case Reports
Start Time	Pub.	Title	Presenter
11:30 AM	020	A Unique Case of Malignant Edema due to Cerebellar Diaschisis Necessitating Decompressive Craniectomy	Disclosure: Dr. Hurtubise has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	021	Role of uric acid and Apo A1 as biomarkers in Idiopathic Parkinson’s Disease and Parkinson Plus Syndromes in North Indian population	Disclosure: Dr. Modi has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	021	Change in Catastrophizing After Onabotulinumtoxin A Treatment in Chronic Migraine with Medication Overuse: Preliminary Findings	Disclosure: Dr. Andrasik has nothing to disclose.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	021	The Mental Rotation Test (MRT) Used as a Clinical Tool to Monitor Disease Progression in EOPD	Disclosure: Dr. Subramanian has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with NIH, Teva, Acadia Pharmaceuticals, Adamas Pharmaceuticals, US WorldMeds, and Neurocrine Biosciences. Dr. Subramanian has received royalty, license fees, or contractual rights payments from Taylor and Francis. Dr. Subramanian has received research support from NIH, PA TSF, APDA, , Anne and Phillip Gladfelter III Foundation, Intec Pharma, and Ron and Pratima Gatehouse Trust.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	021	Multiple Sclerosis Apps: The dawn of a new era: A comprehensive review	Disclosure: Dr. Stoll has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genentech and Genzyme.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	021	In-hospital Delirium and Long-Term Cognitive Outcomes among Patients with Ischemic Stroke: A population-based cohort analysis	Disclosure: Dr. Bambhoroliya has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	021	Elevated Creatine Kinase in Patients with Peripheral Neuropathy	Disclosure: Dr. Macke has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	021	Tolerability and Effectiveness of Adjunctive Lacosamide in Patients with Cerebrovascular Epilepsy Etiology: Exploratory Post-hoc Analysis of A Non-interventional Trial	Disclosure: Dr. Brandt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Arvelle, UCB, Desitin, Idorsia, Eisai, and GW.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	021	Witnessed Apneas During Sleep are Associated with Elevated Tau-PET Signal in the Entorhinal Cortex in Cognitively Unimpaired Elderly	Disclosure: Dr. Carvalho has nothing to disclose.
Neurocritical Care: Case Reports
Start Time	Pub.	Title	Presenter
11:30 AM	021	A Case of Spinal Cord Edema with Cord Compression Due to Systemic Lupus Erythematosus and Osmotic Shifts, Treated with Hypertonic Saline.	Disclosure: Dr. Cahan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Epic.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	022	Autistic Parkinsonism: NBIA with Mosaic WDR45 Mutation and DaTscan positive dopa-Responsiveness	Disclosure: Dr. Zhang has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	022	Association of Conversion Disorder and Migraine	Disclosure: Dr. Krashin has nothing to disclose.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	022	Pareidolia as a Manifestation of Folie á Deux	Disclosure: Dr. khokhar has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	022	Longitudinal Assessment of Retinal Structures in Patients with Relapsing-Remitting Multiple Sclerosis on Fingolimod (Gilenya®)	Disclosure: Dr. Lin has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	022	Review of Current Pharmacotherapy for Post-Stroke Depression	Disclosure: Dr. Syed has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	022	Unexpected Diagnosis of Acute Hemiparesis	Disclosure: Dr. Castrodad- Molina has nothing to disclose.
Epilepsy: Antiseizure Medications II
Start Time	Pub.	Title	Presenter
11:30 AM	022	Inpatient Hospitalization Risk In Patients With Epilepsy Before And After Perampanel Treatment	Disclosure: Dr. Faught has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with As a KOL for Eisai inc.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	022	Clinical Polysomnography Trial of Suvorexant for Treating Insomnia in Alzheimer’s Disease	Disclosure: Dr. Herring has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co., Inc.. Dr. Herring holds stock and/or stock options in Merck & Co., Inc. which sponsored research in which Dr. Herring was involved as an investigator. Dr. Herring holds stock and/or stock options in Merck & Co., Inc.
Neurocritical Care: Case Reports
Start Time	Pub.	Title	Presenter
11:30 AM	022	Successful monitoring and treatment of neurotoxicity in a patient treated with CAR-T-cell therapy enhanced by ocular ultrasound	Disclosure: Dr. Valencia Sanchez has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	023	Secondary Parkinsonism due to Large Anterior Cranial Fossa Meningioma	Disclosure: Dr. Khetarpal has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	023	The Effect of Lacosamide on Chronic Migraine: Retrospective Analysis in a Single Center Healthcare Academic Institute	Disclosure: Dr. Yuan has nothing to disclose.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	023	Left hemispatial neglect with a splenial lesion	Disclosure: Dr. Kesayan has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	023	EDSS and Timed 25 Foot Walk Correlate with Spinal Cord Areas: Baseline Results from the SPI2 Clinical Trial of MD-1003 (high-dose biotin) in Progressive Multiple Sclerosis	Disclosure: Dr. Block has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	023	Dysphagia Severity and Medullary Lesion Localization	Disclosure: Dr. Eliauri has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	023	Complex C1-2 Osteophyte Presenting with Severe Dysphagia and Ptosis	Disclosure: Dr. Amin has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	023	Consequences of diagnostic delay in patients with new onset focal epilepsy characterized by subtle seizures	Disclosure: Dr. Pellinen has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	023	Mindfulness Based Stress Reduction as a treatment for Chronic Insomnia in Traumatic Brain Injury Patients	Disclosure: Dr. Werner has nothing to disclose.
Neurocritical Care: Case Reports
Start Time	Pub.	Title	Presenter
11:30 AM	023	Delayed Symptoms: An Unusual Case of Hypoxic-ischemic Encephalopathy	Disclosure: Dr. Rothstein has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	024	Analysis of a Large Progressive Supranuclear Palsy Cohort Reporting to a Single Clinical Center	Disclosure: Dr. Hanna AL-Shaikh has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	024	Ubrogepant is Effective for the Acute Treatment of Migraine in Patients with an Insufficient Response to Triptans	Disclosure: Dr. Blumenfeld has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Allergan, Amgen, Avanir, Depomed, Eli Lilly, Novartis, Pernix, Promius, Supernus, and Teva.
Behavioral and Cognitive Neurology: Language, Memory, and Visuoperception I
Start Time	Pub.	Title	Presenter
11:30 AM	024	Frontal Cortical Networks in Hemineglect	Disclosure: Dr. Antoniello has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	024	FLOODLIGHT: Smartphone-Based Self-Monitoring Is Accepted by Patients and Provides Meaningful, Continuous Digital Outcomes Augmenting Conventional In-Clinic Multiple Sclerosis Measures	Disclosure: Dr. Montalban has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past 3 years with Biogen Idec, Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Roche, Celgene, Actelion, NMSS and MSIF.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	024	Early Detection Factors of Post-Stroke Dysphagia	Disclosure: Dr. Santos has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	024	Case series on Nitrous Oxide Toxicity	Disclosure: Dr. Pang has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	024	Assessing Factors Influencing Seizure Self-Prediction in a Prospective Randomized Trial	Disclosure: Dr. Hartshorn has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	024	Pitolisant Treatment Improves Multiple Clinical Symptoms of Prader-Willi Syndrome (PWS) in Children	Disclosure: Dr. Pullen has nothing to disclose.
Neurocritical Care: Case Reports
Start Time	Pub.	Title	Presenter
11:30 AM	024	Cerebellar Meningioangiomatosis Presenting as Chronic Headache and Vertigo with Traumatic Subarachnoid Hemorrhage	Disclosure: Dr. Wu has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	025	Is the Latency from Progressive Supranuclear Palsy Onset to Diagnosis Improving?	Disclosure: Dr. Mamarabadi has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	025	Early Detection of Persons at Risk for Incident CM	Disclosure: Dr. Iaconangelo has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Sanofi UCB Allergan Pfizer DRL Insmed Janssen.
Novel Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	025	An inflammatory marker panel provides insight into immune pathways involved in cognition: the Northern Manhattan Study	Disclosure: Dr. Elkind has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott, Vascular Dynamics, Merck/Organon, Auxilium, LivaNovaand. Dr. Elkind has received research support from BMS-Pfizer Alliance, Roche.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	025	Stroke associated pneumonia: Usefulness of a practical and straightforward scale.	Disclosure: Dr. Aldinio has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	025	Severe Central and Peripheral Nervous System Toxicity Associated with Vinblastine in the Treatment of Hodgkins Lymphoma	Disclosure: Dr. Schachter has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	025	Risk factors for readmission in a nationally representative sample of children with epilepsy	Disclosure: Dr. Kessler has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	025	Sleep Disorders and Polysomnographic Findings in Patients with Alternating Hemiplegia of Childhood	Disclosure: Dr. Tran has nothing to disclose.
Neurocritical Care: Case Reports
Start Time	Pub.	Title	Presenter
11:30 AM	025	Relapsing course of refractory neuroleptic malignant syndrome eventually leading to a full recovery	Disclosure: Dr. Giugliano has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	026	Stiff Person Syndrome as a Mimic of Parkinsonism	Disclosure: Dr. Diaz Rojas has nothing to disclose.
Migraine I
Start Time	Pub.	Title	Presenter
11:30 AM	026	Altered Permeability of Blood-CSF Barriers in Migraine	Disclosure: Dr. Cowan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities.
Novel Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	026	Plasma lipocalin-2 levels in the preclinical stage of Alzheimer’s disease	Disclosure: Dr. Eruysal has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	026	Upper limbs impairment in patients with multiple sclerosis: a relevant and currently undervalued measure.	Disclosure: Dr. Alonso has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	026	Delirium is Associated with Increased Readmissions and Mortality in Patients with Acute Ischemic Stroke	Disclosure: Dr. Yi has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	026	Cyclic Sciatica: Presentation of a Case With Intra and Extrapelvic Endometriosis Affecting the Sciatic Nerve and Utility of MR Neurography	Disclosure: Dr. Uribe Roca has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	026	Determining Utility of Additional Days in the Epilepsy Monitoring Unit (EMU) for Patients without Events in First 5 Days of Admission	Disclosure: Dr. Cherayil has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	026	Insomnia in Epilepsy: Association Between Insomnia Symptom Severity and Disease-Related Characteristics	Disclosure: Dr. Somboon has nothing to disclose.
Neurocritical Care: Case Reports
Start Time	Pub.	Title	Presenter
11:30 AM	026	Case Report: B mode ultrasound images of the thoracic spine	Disclosure: Dr. Gomez has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	027	Hospital Utilization Rates Following Antipsychotic Dose Reductions Among Patients With Bipolar and Major Depressive Disorders	Disclosure: Dr. Carroll has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceutical Industries Ltd.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	027	Medical Cannabis in the Treatment of Post-Traumatic Concussion	Disclosure: Dr. McVige has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Promius, Avanir, Gammacore, Depomed, Eli Lilly, Oxtellar, and Teva Pharmaceuticals. Dr. McVige has received research support from Dent Family Foundation.
Novel Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	027	A Highly Sensitive Electrochemiluminescence (ECL) Immunoassay for Measurement of Amyloid Beta1-42 peptide in Human Plasma	Disclosure: Dr. Mehta has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	027	Peripheral nervous system electrodiagnostic abnormalities in Multiple Sclerosis	Disclosure: Dr. Lizarraga has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	027	Higher In-Hospital Mortality, Length of Stay, and 30-day Readmission Rates among Stroke Patients with Delirium: A Population based Analysis	Disclosure: Dr. Vahidy has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	027	Hyperbaric Oxygen Therapy: A Treatment for Radiation Induced Plexopathy	Disclosure: Dr. Verma has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	027	Elevated Healthcare Burden Among Patients with Active Generalized Tonic-Clonic (GTC) Convulsions	Disclosure: Dr. Sheikh has received research support from Eisai Inc..
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	027	Alteration of resting-state functional connectivity in patients with REM sleep behavior disorder (RBD): a cross-sectional study from the J-PPMI cohort	Disclosure: Dr. Wakasugi has nothing to disclose.
Atypical Parkinsonism
Start Time	Pub.	Title	Presenter
11:30 AM	028	The second clinical-pathological study of a FTDP-17 family with a heterozygous splicing variant c.823-10G>T at the intron 9/exon 10 of the MAPT gene.	Disclosure: Dr. Olszewska has nothing to disclose.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	028	Rapidly Progressive Myelopathy due to Fibrocartilaginous Embolism of the Spinal Cord	Disclosure: Dr. Siddiqui has nothing to disclose.
Novel Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	028	Soluble TREM2 CSF concentration in Alzheimer’s disease track VCAM1, known to regulate leukocyte migration into the brain	Disclosure: Dr. Pillai has received personal compensation in an editorial capacity for Current Treatment Options in Neurology.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	028	Disability or Disease: What Stands at the Basis of Connectivity Patterns within the Visual Network following Damage to the Optic Nerve?	Disclosure: Dr. Backner has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	028	Pseudobulbar affect in patients with stroke	Disclosure: Dr. Segamarchi has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	028	Bilateral Diaphragmatic Paralysis As A Complication Of Chiropractic Cervical Manipulation	Disclosure: Dr. Noto has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	028	A new definition of seizure clusters based on temporal clustering patterns in seizure diaries	Disclosure: Dr. Chiang has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	028	Stroke In Population With Sleep Disturbance In Russia/Siberia: Gender Features. WHO Epidemiological Program MONICA-Psychosocial	Disclosure: Dr. Panov has nothing to disclose.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	029	Longitudinal Change in Diffusion Kurtosis Imaging Metrics as a Biomarker of Mild Traumatic Brain Injury.	Disclosure: Dr. Shetty has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GE/NFL Medical Advisory Board. Dr. Shetty has received research support from General Electric, National Football League, Chembio/Perseus, ElMindA and Teva Pharmaceuticals.
Novel Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	029	Identification and Preliminary Validation of a Plasma Profile Associated with Cognitive Decline in Dementia and At-risk Individuals: A Retrospective Cohort Analysis	Disclosure: Dr. Iulita has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	029	Transcranial Direct Current Stimulation (tDCS) can Enhance Physical Training Outcomes in Multiple Sclerosis (MS)	Disclosure: Dr. Pilloni has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	029	Impact of Anemia on Stroke Morbidity and Mortality	Disclosure: Dr. Shapouran has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	029	A Retrospective Chart Review of 49 Patients referred for Skin Punch Biopsy for Small Fiber Neuropathy Symptoms	Disclosure: Dr. Bajwa has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	029	Quality of Epilepsy Care in Medicaid-only Neurology Resident Clinic	Disclosure: Dr. Waldman has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	029	Sleep Quality Correlates with the Carotid intima-media Thickness in Stroke-free community-dwelling adults	Disclosure: Dr. Castillo has nothing to disclose.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	029	Prevalence, Benefits, and Adverse Effects of Cannabis Use in Parkinson’s Patients	Disclosure: Dr. Carwin has nothing to disclose.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	030	Does a Post-Concussion Change in King-Devick Score Predict Return to Play in Collegiate Athletes?	Disclosure: Dr. Hunzinger has nothing to disclose.
Novel Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	030	Age-Related Differences in Electrophysiological Activity in Response to Increasing Sensory Degradation and Visual Task Demands	Disclosure: Dr. Daffner has nothing to disclose.
MS Clinical Assessments and Outcome Measures
Start Time	Pub.	Title	Presenter
11:30 AM	030	Understanding Motor Performance in People with Multiple Sclerosis Using Virtual Reality	Disclosure: Dr. El-Salem has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	030	Socio-Demographic and Clinical Study of Post Stroke Cognitive Decline: A Hospital Based Study	Disclosure: Dr. Chaurasia has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	030	A 69-year-old woman with diplopia and lower extremity weakness: A case of Bing-Neel Syndrome	Disclosure: Dr. Migdady has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	030	The Clinical Outcome of Non-Diagnostic Epilepsy Monitoring Unit (EMU) Studies	Disclosure: Dr. Amin has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	030	Severity of Obstructive Sleep Apnea and Burden of Cerebral Microbleeds in Patients with Atrial Fibrillation	Disclosure: Dr. Vilanilam has nothing to disclose.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	030	A Pooled Analysis for Eight Randomized Controlled Trials of Istradefylline, an Adenosine A_2A Receptor Antagonist: Efficacy as Adjunct to Levodopa in Parkinson’s Disease (PD)	Disclosure: Dr. Isaacson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Acadia, Acorda, Adamas, Addex, Allergan, Amarantus, Avid, Axovant, AZTherapies, Biogen, Britannia, Eisai, Eli Lilly, Enterin, GE Healthcare, Impax, Intec Pharma, Ipsen, Kyowa, Lundbeck, Michael J. Fox Foundation, Neurocrine, NeuroDerm, NINDS/NIH, Parkinson Study Group, Pfizer, Pharma Two B, Roche, Sanofi, Sunovion, Teva, UCB, US WorldMeds, and Zambon. Dr. Isaacson has received research support from Abbvie, Acadia, Acorda, Adamas, Amarantus, Axovant, AZ Therapies, Benevolent, Biogen, Cavion, Eli Lilly, Enterin, Impax, Intec Pharma, Jazz, Ipsen, Kyowa, Lundbeck, Michael J. Fox Foundation, Neuroderm, Parkinson Study Group, Pfizer, Pharma2B, Roche, Sanofi, Sunovion, Teva, UCB, US WorldMeds.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	031	Pediatric Concussion Treatment: Occupational Therapy’s Role in Identifying Impacted Occupational Domains	Disclosure: Dr. Harris has nothing to disclose.
Novel Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	031	Novel method utilizing Arterial Spin Labeling single acquisition 3D Echo Planar Imaging for determining CNS Glymphatic Clearance	Disclosure: Dr. Joseph has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	031	Reduction in 48-Week Confirmed Disability Progression After 5.5 Years of Ocrelizumab Treatment in Patients With Primary Progressive Multiple Sclerosis	Disclosure: Dr. Wolinsky has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received compensation for consulting, scientific advisory boards, or other activities with Alkermes, Actelion, Acorda Therapeutics, Celgene, EMD Serono, GeNeuro, GW Pharma, MedDay Pharmaceuticals, Novartis, Otsuka, PTC Therapeutics, Roche/Genentech, Sanofi Genzyme; CME activities with PlatformQ Health Education, PRIME, Strategic Consultants Intl.. Dr. Wolinsky has received royalty, license fees, or contractual rights payments from Royalties are received for out-licensed monoclonal antibodies through UTHealth from Millipore Corporation.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	031	The Obesity Paradox Characterizes Outcome from Acute Ischemic Stroke: Evidence from 1033 Patients	Disclosure: Dr. Liu has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	031	Evaluating IVIG Dosing Strategies in Neurologic Indications & Outcomes	Disclosure: Dr. Nguyen has nothing to disclose.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	031	Telemedicine for epilepsy patients – an emergence of the 21st century clinic	Disclosure: Dr. Reider-Demer has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	031	Upper Airway Stimulation Therapy Predictors for Treatment of Obstructive Sleep Apnea	Disclosure: Dr. Waters has received research support from Inspire Medical Systems, Inc.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	031	In silico drug screening by using genome-wide association study (GWAS)-data repurposed dabrafenib, an anti-melanoma drug, for Parkinson’s disease	Disclosure: Dr. Uenaka has nothing to disclose.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	032	Twinning with Concussions	Disclosure: Dr. Alessi-LaRosa has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	032	Long-term Effect of Fingolimod in Reducing Blood Neurofilament Light Levels in Patients with Relapsing-remitting Multiple Sclerosis	Disclosure: Dr. Cohen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting from Adamas, Celgene, Convelo, EMD Serono, Novartis, and PendoPharm; speaking for Mylan. Dr. Cohen has received personal compensation in an editorial capacity for Co-Editor of Multiple Sclerosis Journal – Experimental, Translational and Clinical.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	032	Patients with Dementia or Stroke Hospitalized with Community-acquired pneumonia are at Higher Risk of Long-term Mortality	Disclosure: Dr. Yeruva has nothing to disclose.
Acquired Neuropathies II
Start Time	Pub.	Title	Presenter
11:30 AM	032	A retrospective chart review to assess the efficacy and tolerability of switching from an alternative brand of IVIG to Panzyga® in patients with autoimmune neuromuscular disorders	Disclosure: Dr. Campbell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Octapharma.
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	032	Seizure Comorbidity Increases Odds Of 30-Day Readmission After an Index Hospitalization for Sepsis	Disclosure: Dr. Fox has nothing to disclose.
Interface of Sleep and Neurology
Start Time	Pub.	Title	Presenter
11:30 AM	032	Impact of Upper Airway Stimulation Treatment for Obstructive Sleep Apnea on Comorbid Insomnia, Depression and Sleepiness Patient Reported Outcome Measures	Disclosure: Dr. Waters has received research support from Inspire Medical Systems, Inc.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	032	APOmorphine infusion and aMYLoid deposition in Parkinson’s disease (APOMYL): preliminary clinical and amyloid imaging data	Disclosure: Dr. van Wamelen has received research support from Britannia Pharmaceuticals.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	033	Ground Reaction Force Patterns in the Golf Swing-Role in Injury Prevention and Performance	Disclosure: Dr. Giombetti has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	033	Effect of Ibudilast on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial	Disclosure: Dr. Fox has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received compensation for serving as consultant or speaker from from Actelion, Biogen, EMD Serono, Genentech, Novartis, and Teva. Dr. Fox has received research support from Biogen (clinical trial contracts) and Novartis (research study support)..
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	033	Factors Affecting Readmission Rates for Patients with Ischemic Stroke Hospitalized in an Integrated Health System of Stroke Care	Disclosure: Dr. Le has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	033	Familial Amyloid Polyneuropathy: Impact of Biopsies and Mutations on Diagnostic Considerations	Disclosure: Dr. Gibbons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck Inc.. Dr. Gibbons has received personal compensation in an editorial capacity for Associate Editor for Autonomic Neuroscience: Basic and Clinical. Dr. Gibbons holds stock and/or stock options in Cutaneous NeuroDiagnostics. Dr. Gibbons has received research support from Grifols Inc..
Epilepsy: Diagnosis and Clinical Care II
Start Time	Pub.	Title	Presenter
11:30 AM	033	The Effect of Completing a Neurology Clerkship on Diagnostic Accuracy of Paroxysmal Spells	Disclosure: Dr. Hanrahan has nothing to disclose.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	033	Defining Disrupted Nighttime Sleep (DNS) in Pediatric Narcolepsy	Disclosure: Dr. Maski has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals, Inc and Harmony Biosciences, Inc. Dr. Maski has received royalty, license fees, or contractual rights payments from UptoDate, Inc. Dr. Maski holds stock and/or stock options in Sanofi/Genzyme, Inc. Dr. Maski has received research support from Jazz Pharmaceuticals, Inc.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	033	Impact of carbidopa-levodopa enteral suspension on quality of life and activities of daily living in patients with advanced Parkinson's Disease: Results from a pooled meta-analysis	Disclosure: Dr. Standaert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Serina Therapeutics, Abbvie Inc., the Michael J. Fox Foundation for Parkinson Research, The International Parkinson Disease and Movement Disorder Society, The Parkinson Foundation, the National Institutes of Health, Oregon Health Sciences University, Voyager Therapeutics, Blue Rock Therapeutics, Clintrex LLC, Revivo Therapeutics, Sanofi-Adventis Research and Development, and US Department of Justice. Dr. Standaert has received license feed payments, royalties, or contractual rights from McGraw Hill, Inc. Dr. Standaert has received research support from Abbvie, Inc., Avid Radiopharmaceuticals, the American Parkinson Disease Association, the Michael J. Fox Foundation for Parkinson Research, Alabama Department of Commerce, the Bachmann-Strauss Dystonia; Parkinson Foundation, and NIH grants.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	034	Indirect Gunshot Spinal Cord Injury: A Case Report and Review of Literature	Disclosure: Dr. Chedid has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	034	Evaluation of shorter infusion times with ocrelizumab in patients with relapsing-remitting multiple sclerosis	Disclosure: Dr. Vollmer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Academic CME, Alcimed, Anthem Blue Cross, Genentech/Roche, Biogen IDEC, Novartis, CellGene, Epigene, Rocky Mountain MS Center, GLG Consulting, Ohio Health, TG Therapeutics, Topaz Therapeutics, Dleara Lawyers, Teva. Dr. Vollmer has received research support from Teva, NIH/NINDS, Rocky Mountain MS Center, Actelion, Roche/Genentech, UT Southwestern, TG Therapeutics.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	034	Hemorrhagic Complications after Acute Stroke Therapies Are Not Elevated in Patients with Chronic Kidney Disease, with or without Hemodialysis	Disclosure: Dr. Schachter has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	034	Autosomal Recessive Charcot-Marie-Tooth Disease in Turkey	Disclosure: Dr. Cakar has nothing to disclose.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	034	Efficacy and Safety of Pitolisant in Patients With Narcolepsy: A Review of Clinical Trials	Disclosure: Dr. Dauvilliers has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bioprojet, Flamel Technologies S.A. (now Avadel Pharmaceuticals plc), Harmony Biosciences, LLC, Idorsia Pharmaceuticals Ltd., Jazz Pharmaceuticals, Takeda Pharmaceutical Co. Ltd., Theranexus, and UCB Pharma.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	034	Population Pharmacokinetics Model of Apomorphine/Apomorphine-Sulphate Administered as a Sublingual Film or Subcutaneously in Healthy Subjects and Patients With Parkinson’s Disease	Disclosure: Dr. Agbo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion Pharmaceuticals Inc.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	035	Relationships Between Self-reported Anger, Aggression, and Concussion History in Hockey Players	Disclosure: Dr. DiFabio has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	035	Optimal Response to Dimethyl Fumarate is Mediated by a Reduction of Th17.1 cells after 3 Months of Treatment	Disclosure: Dr. Mansilla has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	035	High Dietary Glycemic Load is Associated with Poor Functional Outcome in Patients with Acute Cerebral Infarction	Disclosure: Dr. Lee has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	035	Hereditary Sensory Autonomic Neuropathy Type-1C (HSAN1c) by a Novel Mutation of Asn177Asp in SPTELCS2 Gene	Disclosure: Dr. Anderson has nothing to disclose.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	035	Hormonal Contraceptive and Pitolisant CYP3A4 Induction	Disclosure: Dr. Robert has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Reports being an employee of Bioprojet Biotech.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	035	NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update	Disclosure: Dr. Simuni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia, Adamas, Teva, Abbvie, Anavex, Allergan, Accorda, Neuroderm, Photopharmics, Revance, Sanofi, Sunovion, Voyager, US World Meds, and the Michael J. Fox Foundation, Denali,Neurocrine, Takeda, Dr. Simuni has received research support from Biogen, Roche, Neuroderm, Sanofi, Sun Pharma, NINDS, the Michael J. Fox Foundation, and the Parkinson Foundation.
Neuro Trauma and Sports Neurology II
Start Time	Pub.	Title	Presenter
11:30 AM	036	Blast Traumatic Brain Injury: Developing Personalized 3D Computational Models for use in High-Fidelity Blast Physics Simulations using Human MRI Scans	Disclosure: Dr. Elsbernd has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	036	Ozanimod Efficacy in Relapsing Multiple Sclerosis Supported by Open-Label Long-Term Extension of Two Phase 3 Trials	Disclosure: Dr. Steinman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Celgene, Merck, Coherus, Atreca. Dr. Steinman has received compensation for serving on the Board of Directors of Atreca, Tolerion. Dr. Steinman has received royalty, license fees, or contractual rights payments from Tolerion. Dr. Steinman has received research support from Coherus, Celgene.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	036	Factors Associated With Outpatient Neurology Clinic Follow-Up After Acute Stroke Hospitalization at a Large Public City Hospital	Disclosure: Dr. Tiu has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	036	A Triad of CMT1A Hereditary Neuropathy, Anti-neurofascin-155 IgG Antibodies and Relapsing Remitting Multiple Sclerosis	Disclosure: Dr. Grebenciucova has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Multiple Sclerosis Association of America, Presence Health, and Tenet Healthcare Corporation.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	036	Burden of Narcolepsy: A Survey of Patients and Physicians	Disclosure: Dr. Thorpy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Balance Therapeutics, Harmony Biosciences, LLC, Jazz Pharmaceuticals, Merck & Co. Dr. Thorpy has received research support from Balance Therapeutics, Harmony Biosciences, LLC, and Jazz Pharmaceuticals.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	036	Safety and Efficacy of Solriamfetol for the Treatment of Excessive Daytime Sleepiness in Parkinson’s Disease in a Four-Week Double-blind, Placebo-controlled Randomized Crossover Study	Disclosure: Dr. Videnovic has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Jazz and Wilsons Therapeutics.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	037	Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study)	Disclosure: Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	037	Screening and Treatment for Osteoporosis after Stroke: Results from the Ontario Stroke Registry	Disclosure: Dr. Kapoor has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	037	A Giant Axonal Neuropathy (GAN)-like syndrome due to a mutation in Microtubule Associated Protein 1B (MAP1B): a new syndrome.	Disclosure: Dr. Cupler has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi, and Novartis.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	037	Misdiagnoses and Comorbidities among Participants in the Nexus Narcolepsy Registry	Disclosure: Dr. Ohayon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals. Dr. Ohayon has received research support from Takeda.
Parkinson's Disease Therapeutics II
Start Time	Pub.	Title	Presenter
11:30 AM	037	A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson’s Disease	Disclosure: Dr. Rosebraugh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie. Dr. Rosebraugh holds stock and/or stock options in Abbvie.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	037	Transient Paralysis in the Setting of Thyrotoxicosis and Concurrent Stimulant Overdose	Disclosure: Dr. Sambursky has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	038	Incidence of Relapses in Patients with Biotin-Treated Progressive Multiple Sclerosis (IPBio-SeP Study): Intermediate Analysis of a French, Multicenter Study	Disclosure: Dr. Mathais has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	038	Disease, Institutional and Community Factors Influencing Compliance in Stroke Patient Follow-up	Disclosure: Dr. Sun has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	038	A Novel Myelin Protein Zero variant in Charcot-Marie-Tooth Disease Type 2I	Disclosure: Dr. Kushlaf has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genzyme, Alexion, PTC therapeutics, Catalyst pharmaceuticals.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	038	Healthcare Cost and Utilization Before and After Diagnosis in Pediatric Patients With Newly Diagnosed Narcolepsy: A Claims-based Analysis	Disclosure: Dr. Reiss Reddy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Partnership for Health Analytic Research LLC. Dr. Reiss Reddy has received research support from Partnership for Health Analytic Research LLC to conduct this research.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	038	Reducing Complications in Hospitalized Parkinson's Patients	Disclosure: Dr. Aslam has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	038	Botulinum toxin type A overdoses: analysis of the FDA adverse event reporting system database	Disclosure: Dr. Kazerooni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz North America.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	039	Serum Neurofilament Light Chain in a Phase 1/2 Trial of Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis	Disclosure: Dr. Baldassari has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	039	Proportional Recovery in Post-Stroke Aphasia	Disclosure: Dr. Bailey has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	039	Variant of Uncertain Significance in Charcot Marie Tooth Disease: GDAP1 Protein Modeling and Phenotype Correlation	Disclosure: Dr. Cline has nothing to disclose.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	039	A Longitudinal Study of Hypersomnolence in the US General Population and its Chronicity	Disclosure: Dr. Ohayon has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals. Dr. Ohayon has received research support from Takeda.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	039	The Association of Gut Microbiome Composition and Parkinson’s Disease in Patient Cohort of Central California	Disclosure: Dr. Chou has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	039	Myelopathy in the setting of fentanyl abuse	Disclosure: Dr. Tong has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	040	Multiple Sclerosis (MS) Relapse Rates and Healthcare Costs with Generic Glatiramer Acetate: a Retrospective Claims Analysis of US Health Plan Data	Disclosure: Dr. Hall has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sandoz.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	040	A protocol for acute neurofunctional rehabilitative therapy following ischemic stroke	Disclosure: Dr. Andrade has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	040	Early Onset Ataxia in a Patient with CMT2A2	Disclosure: Dr. Madrid has nothing to disclose.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	040	The Cumulative Effect of Partial Chronic Sleep Restriction on Objective Daytime Sleepiness in Neurologically Healthy Individuals	Disclosure: Dr. Feemster BA has nothing to disclose.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	040	Estimating an Individual’s Risk of Parkinson’s Disease based on Comprehensive Family History	Disclosure: Dr. Moretti has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	040	Axonal Neuropathy, Myelopathy and Hypercoagulable State Secondary to Chronic Nitrous Oxide Abuse Despite Combined B12 Supplementation	Disclosure: Dr. Olney has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	041	Meta-analysis of real-world adherence and persistence of maintenance once- or twice-daily oral disease-modifying drugs (dimethyl fumarate, fingolimod, and teriflunomide) in multiple sclerosis	Disclosure: Dr. Phillips has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Inc.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	041	Limbic Atrophy in Post-Stroke Epilepsy: a Voxel Based Morphometry Study	Disclosure: Dr. Katsurayama has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	041	Prospective 16-year Longitudinal Study of Dominant Intermediate CMT Type C Neuropathy	Disclosure: Dr. Pan has nothing to disclose.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	041	A D1 receptor positive allosteric modulator (LY3154207) enhances wakefulness in sleep deprived healthy volunteers	Disclosure: Dr. Biglan holds stock and/or stock options in Eli Lilly and Company.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	041	Rab GTPase Expression Changes in a-Synucleinopathy and Tauopathy Disorders	Disclosure: Dr. Parmar has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	041	Acute visual disturbance associated with hydrogen peroxide ingestion	Disclosure: Dr. Lee has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	042	Reduced Rate of Brain Atrophy in Patients With PPMS Receiving Ocrelizumab Earlier and Continuously Versus Those Initiating Ocrelizumab Later: Results of ORATORIO 5-Year Follow-Up	Disclosure: Dr. Arnold has nothing to disclose.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	042	Botulinum toxin A modulates parietal cortex activity in post-stroke upper limb spasticity	Disclosure: Dr. Hlustik has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	042	The Yield of Targeted Gene Panels in Axonal Neuropathies	Disclosure: Dr. Lee has nothing to disclose.
Narcolepsy and Hypersomnolence
Start Time	Pub.	Title	Presenter
11:30 AM	042	Commercially-available wearable provides valid estimate of sleep stages	Disclosure: Dr. Stevens has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Jazz Pharmaceuticals and Inspire. Dr. Stevens has received research support from Garmin.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	042	The effect of race on accuracy of coding with ICD-10 code G20	Disclosure: Dr. Patel has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	042	Acute reversible cerebral vasoconstrictive syndrome after treatment with Ketamine and Dihydroergotamine	Disclosure: Dr. Yuan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Supernus.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	043	Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Long-term Safety Data at 48 Months of Follow-up	Disclosure: Dr. De Seze has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi-Genzyme, Teva, Novartis, Roche, Chugai, and Alexion. Dr. De Seze has received research support from Sanofi.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	043	Patient Perception Confounds True Recovery After Stroke	Disclosure: Dr. Marsh has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	043	Assessing the immediate effect of ground reaction ankle foot orthoses on balance in individuals with inherited neuropathies	Disclosure: Dr. Burke has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	043	Differentiation of Autonomic Dysfunction in Multiple System Atrophy Sub types and Idiopathic Parkinson’s Disease	Disclosure: Dr. Garg has nothing to disclose.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	043	Characteristics of Homebound Medicare Beneficiaries with Parkinson Disease	Disclosure: Dr. Mendizabal has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	043	Neurotoxicity from Intrathecal Gadolinium Administration (IT-Gad)	Disclosure: Dr. Calvo has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	044	Modified Ketogenic Diet Therapy for Relapsing Multiple Sclerosis: Patient-Reported Outcomes	Disclosure: Dr. Brenton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	044	Implementing a Sustainable Plan for the COAST Stroke Advance Directive	Disclosure: Dr. Chiang has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	044	Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation: Two Siblings with A Novel Mutation in The DARS2 Gene.	Disclosure: Dr. yelam has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	044	Withering Hearts: Spectrum of Cardiovascular Autonomic Dysfunction and 24hour Blood Pressure Variability in Early Idiopathic Parkinson’s Disease	Disclosure: Dr. Sebastian has nothing to disclose.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	044	Association of Motor and Non Motor Symptoms Severity with Motor Laterality Asymmetry in Parkinson´s Disease	Disclosure: Dr. Cubo Delgado has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	044	Headache, visual loss, and encephalopathy associated with intravenous ozone administration	Disclosure: Dr. Tong has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	045	Effect of Alemtuzumab on Serum Neurofilament Light Chain Levels: Comparison to SC IFNB-1a and Assessment Over 7 Years (CARE-MS I)	Disclosure: Dr. Kuhle has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Scientific advisory boards for Novartis Pharmaceuticals, Merck, Biogen, Sanofi Genzyme, Roche and Bayer. Funding for travel and/or speaker honoraria from Biogen, Sanofi Genzyme, Novartis, Merck Serono, Roche, Teva and the Swiss MS Society.. Dr. Kuhle has received research support from Consulting fees from Biogen, Novartis, Protagen AG, Roche, Teva; speaker fees from the Swiss MS Society, Biogen, Novartis, Roche, Genzyme; travel expenses from Merck Serono, Novartis, Roche; grants from ECTRIMS Research Fellowship Programme, University of Basel, Swiss MS Society, Swiss National Research Foundation (320030_160221), Bayer AG, Biogen, Genzyme, Merck, Novartis, Roche.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	045	Non-high-density lipoprotein cholesterol is associated with hemorrhagic transformation after acute ischemic stroke	Disclosure: Dr. Wang has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	045	GDAP1-Related Charcot-Marie-Tooth Disease: Additional Evidence for the c.692C>T Variant as a Pathogenic Mutation	Disclosure: Dr. Vivar has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	045	Diagnosis and Treatment of Neurogenic Orthostatic Hypotension: Online, Case-based Education Successfully Improved Knowledge and Competence of Cardiologists and Neurologists	Disclosure: Dr. Maeglin has nothing to disclose.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	045	Outcomes of Elective Orthopedic Surgery in Parkinson’s disease – a Nationwide Study	Disclosure: Dr. Fullard has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	045	PPI Induced Hypomagnesemic Hypoparathyroidism Leading to PRES Syndrome	Disclosure: Dr. Moheb has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	046	Investigating the Effect of Teriflunomide on Brain Volume Loss in the Phase 3 TOPIC Study	Disclosure: Dr. Sprenger has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with The employer of Dr Sprenger received compensation for his serving on scientific advisory boards and/or speaking from Sanofi Genzyme, Novartis, Actelion, Merck, Teva, Eli Lilly..
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	046	Females Have Worse In-hospital Outcomes After Reperfusion Therapy in Ischemic Stroke	Disclosure: Dr. Jillella has nothing to disclose.
Genetic Neuropathies
Start Time	Pub.	Title	Presenter
11:30 AM	046	A Case of Recurrent Fever, Encephalopathy, and Unilateral Weakness	Disclosure: Dr. Elsehety has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	046	The Relationship Between Changes in Orthostatic Blood Pressure and Symptoms in Patients with Orthostatic Hypotension	Disclosure: Dr. Freeman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abide, Applied Therapeutics, Astellas, Aptinyx, Biogen, Biohaven, Lundbeck, NeuroBo, Novartis, Pfizer, Regenacy, Spinifex, Toray and Theravance. Dr. Freeman has received personal compensation in an editorial capacity for Autonomic Neuroscience - Basic and Clinical. Dr. Freeman has received compensation for serving on the Board of Directors of NeuroBo. Dr. Freeman holds stock and/or stock options in NeuroBo.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	046	Trajectories of cognitive and functional decline in Parkinson’s disease	Disclosure: Dr. Goldman has received personal compensation for consulting, serving on a scientific advisory board, speaking, and other activities with Acadia, Sunovion, and Worldwide Med. Dr. Goldman has received research support from the Michael J. Fox Foundation and the Parkinson's Foundation.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	046	Hypercalcemic Encephalopathy As An Initial Manifestation Of Hyperthyroidism Due To Endemic Goiter In Mexican Highlands, And Simultaneous Primary Hyperparathyroidism, A Case Report.	Disclosure: Dr. Arbeu Reyes has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	047	Tolerogenic dendritic cell-based treatment in multiple sclerosis (MS): Interim results of two phase I clinical trials.	Disclosure: Dr. Presas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis. Dr. Presas has received research support from Novartis, Biogen, and Merck.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	047	Effect of Anti-Hypertensive Medications on Hemorrhagic Transformation in Ischemic Stroke	Disclosure: Dr. Roman Casul has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	047	Droxidopa and Midodrine Treatment Persistence in Patients With Orthostatic Hypotension	Disclosure: Dr. Hewitt has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	047	Infection and Parkinson's Disease: a Systematic Review and Meta-analysis	Disclosure: Dr. Elfaituri has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	047	Myoclonus – A Rare Presentation of Myxedema Coma	Disclosure: Dr. Malik has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	048	Open Label Extension (OLE) of Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Patients with Relapsing Forms of Multiple Sclerosis (RMS)	Disclosure: Dr. Fox has received honoraria for advisory, consulting, speakers' bureau, and/or research support from Acorda, Bayer, Biogen, Celgene, Chugai, EMD Serono, Genentech Roche, Mallinkrodt, MedDay, Novartis,Teva, and TG Therapeutics.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	048	A Task-Based Approach to Quantifying Movement Deficits Due to Stroke	Disclosure: Dr. Cahn has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	048	Effects of Droxidopa Treatment for Neurogenic Orthostatic Hypotension in Patients Concomitantly on Dopa Decarboxylase Inhibitors	Disclosure: Dr. Kymes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck and CVS Health. Dr. Kymes holds stock and/or stock options in Lundbeck that is greater than $10,000 in value which sponsored research in which Dr. Kymes was involved as an investigator.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	048	Intensity-based exercise groupings in Parkinson’s Disease: Analysis from the Parkinson’s Foundation Quality Improvement Initiative (PF-QII)	Disclosure: Dr. Larson has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	048	Olfactory Hallucinations as a Unique Presentation of Anti-depressant Discontinuation Syndrome	Disclosure: Dr. Varade has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	049	Effect of ibudilast on macular measures in progressive MS: OCT analysis from a phase II trial	Disclosure: Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, Novartis, Roche. Dr. Bermel has received research support from Biogen, Genentech, Roche.
Stroke Continuum of Care II: Post-Stroke Complications, Recovery and Outcomes
Start Time	Pub.	Title	Presenter
11:30 AM	049	External validation of SICH predicting scores	Disclosure: Dr. Nisar has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	049	Postprandial Hypotension in Parkinson’s Disease and Multiple System Atrophy	Disclosure: Dr. Peltier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with CSL Behring, Lundbeck Pharmaceutical Companies, and Alnylam.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	049	Infections leading to hospitalization or sepsis preceding clinically diagnosed a-synucleinopathies: a case-control study in Olmsted County, MN (1991-2010).	Disclosure: Dr. Hasan has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	049	Revisit: Clinical, Laboratory And Electrodiagnositc Features Of Zinc Deficiency-Induced Peripheral Neuropathy	Disclosure: Dr. Rahimian has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	050	Alemtuzumab Outcomes After Switching From Fingolimod In Real-Life Clinical Practice	Disclosure: Dr.Gonzalez has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Sanofi, Biogen, Merck, Serono, Roche, Novartis.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	050	Artery of Percheron Infarct: A difficult diagnosis in the emergency room. Report of 7 cases in Argentina	Disclosure: Dr. Bandeo has nothing to disclose.
Autonomic Disorders: Orthostatic Hypotension and Synucleinopathies
Start Time	Pub.	Title	Presenter
11:30 AM	050	MRI Morphometry in Early Multiple System Atrophy: Correlations with Indices of Disease Burden & Tracking Progression	Disclosure: Dr. Vemuri has nothing to disclose.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	050	Comparison of a Standardized Treadmill Perturbation to the Pull Test to Assess Postural Instability in Parkinson's Disease	Disclosure: Dr. Stutz has nothing to disclose.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	050	Clinical Manifestations Of Peripheral Neuropathy In Patients With Erectile Dysfunction And Testosterone Deficiency	Disclosure: Dr. Rahimian has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	051	Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis	Disclosure: Dr. Benedict has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Novartis, Genzyme, Sanofi, Genentech, Neurocog Trials, Takeda, and Roche . Dr. Benedict has received royalty, license fees, or contractual rights payments from Psychological Assessment Resources. Dr. Benedict has received research support from Biogen, Genentech, Genzyme.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	051	Door to stroke alert timing quality improvement project	Disclosure: Dr. Luster has nothing to disclose.
Autonomic Dysfunction: POTS and Peripheral Nerve
Start Time	Pub.	Title	Presenter
11:30 AM	051	Insurance Denial for Intravenous Immunoglobulin Therapy Effects Patients with Autoimmune Gastrointestinal Dysmotility	Disclosure: Mr. Edelbrock has nothing to disclose.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	051	Medication adherence and discontinuation in a national cohort of Medicare beneficiaries with Advanced Parkinson’s Disease	Disclosure: Dr. Dahodwala has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acadia. Dr. Dahodwala has received research support from AbbVie, Roche, Ely Lilly and CalaHealth.
General Neurology: Neurologic Disease Due to Overdose, Intoxication, or Deficiency
Start Time	Pub.	Title	Presenter
11:30 AM	051	Vitamin B12 deficiency presenting with acute psychosis	Disclosure: Dr. Zimba has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	052	Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis	Disclosure: Dr. Flechter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mapi Pharma Ltd.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	052	Resident stroke simulation improves decision-making and door to needle time in Community Hospital.	Disclosure: Dr. Singh has nothing to disclose.
Autonomic Dysfunction: POTS and Peripheral Nerve
Start Time	Pub.	Title	Presenter
11:30 AM	052	Thermoregulatory Sweat Testing in Sensory Neuronopathies	Disclosure: Dr. Saw has nothing to disclose.
Parkinson's Disease Clinical Features and Clinical Care I
Start Time	Pub.	Title	Presenter
11:30 AM	052	Dysautonomia Predicts Progression to Functional Dependence in Early Parkinson’s Disease	Disclosure: Dr. Miller-Patterson has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	052	Ropinirole Hydrochloride Remedy for Amyotrophic Lateral Sclerosis	Disclosure: Dr. Takahashi has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	053	Ocrelizumab Safety and Effectiveness in the One Year Treatment of Multiple Sclerosis Compared to Other Disease Modifying Therapies	Disclosure: Dr. Alimohamadi has nothing to disclose.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	053	Better Systems, Better Patient Care	Disclosure: Dr. Rios has nothing to disclose.
Autonomic Dysfunction: POTS and Peripheral Nerve
Start Time	Pub.	Title	Presenter
11:30 AM	053	Postural Tachycardia Syndrome might be a Cause of Cerebrospinal Fluid Hypovolemia	Disclosure: Dr. Araki has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	053	Cyclical Vomiting Associated with a Focal Lesion of the Area Postrema Successfully Managed with Medical Marijuana	Disclosure: Dr. Hirsch has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	054	Long-Term Reduction in 48-Week Confirmed Disability Progression After 5 Years of Ocrelizumab Treatment in Patients With Relapsing Multiple Sclerosis	Disclosure: Dr. Hauser has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Annexon, Symbiotix, Bionure and Neurona; he has also received travel reimbursement from F. Hoffmann-La Roche Ltd and Novartis for CD20-related meetings and presentation.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	054	Evaluation of A Rapid Outpatient Stroke Clinic for TIA and Minor Stroke Patients in the Emergency Department	Disclosure: Dr. Mehendale has nothing to disclose.
Autonomic Dysfunction: POTS and Peripheral Nerve
Start Time	Pub.	Title	Presenter
11:30 AM	054	Autonomic manifestations after initiating TTR stabilizer in ATTR amyloidosis.	Disclosure: Dr. Gonzalez Duarte has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	054	Rebound Pain in a Patient Taking Medical Marijuana for Phantom Limb Syndrome	Disclosure: Dr. Hirsch has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	055	Treatment With Additional Courses of Alemtuzumab Improves Clinical and MRI Outcomes in RRMS Patients With Disease Activity After Three Courses: Analysis of CARE-MS Patients Who Received =4 Courses	Disclosure: Dr. Berkovich has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva. Dr. Berkovich has received research support from Acorda, Avanir, Bayer, Biogen, Novartis, Questcor, Sanofi, and Teva.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	055	A Comparison of the Evaluation and Treatment of Transient Ischemic Attack in a Comprehensive Stroke Center and Four Acute Stroke Ready Hospitals	Disclosure: Dr. Jarnot has nothing to disclose.
Autonomic Dysfunction: POTS and Peripheral Nerve
Start Time	Pub.	Title	Presenter
11:30 AM	055	Multi-sensory gain abnormalities in postural tachycardia syndrome exceed those of migraine	Disclosure: Dr. Millsap has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	055	Does Lamotrigine Work for Migraine-Associated Vertigo Better than Topiramate?	Disclosure: Dr. Jaffri has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	056	Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE)	Disclosure: Dr. Smoot has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi Genzyme, Genentech, EMD Serono, Novartis Pharmaceuticals, and Teva. Dr. Smoot has received research support from Biogen and Genentech.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	056	Acute Bacterial Parotitis: A Rare Complication of Orolingual Angioedema Associated with IV Alteplase	Disclosure: Dr. Rondeau has nothing to disclose.
Autonomic Dysfunction: POTS and Peripheral Nerve
Start Time	Pub.	Title	Presenter
11:30 AM	056	Sweat Gland Nerve Fiber Density: Development of a Novel, Unbiased 3D Reconstruction Methodology	Disclosure: Dr. Minota has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	056	Pilot cross-sectional trial of localized transcutaneous magnetic stimulation shows improvement in foot pain secondary to plantar fasciitis (PF), diabetic neuropathy (DN), and chemotherapy neuropathy (CM)	Disclosure: Dr. Shamim has received research support from Kaiser Permanente MidAtlantic Permanente Medical Group.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	057	Real-World Effectiveness of Alemtuzumab in Relapsing-Remitting MS Patients in Germany: Interim Results of the TREAT-MS Study	Disclosure: Dr. Akgün has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, and Roche.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	057	The Existential Problem of Thrombolysis Aborted Stroke: A Case Presentation and Systematic Review	Disclosure: Dr. Bush has nothing to disclose.
Autonomic Dysfunction: POTS and Peripheral Nerve
Start Time	Pub.	Title	Presenter
11:30 AM	057	Correlating Pathologic and Physiologic Measures in Ross Syndrome	Disclosure: Dr. Loavenbruck has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	057	Effect of L-methylfolate on Depressive Symptoms in Patients with MTHFR Mutations	Disclosure: Dr. Rainka has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Postgraduate Healthcare Education, LLC, and Biogen. Dr. Rainka has received research support from Alexa, Acadia, ASHP, Dent Family Foundation.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	058	Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS II (TOPAZ Study)	Disclosure: Dr. Singer has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Received consulting and/or speaking fees from AbbVie, Acorda, Bayer, Biogen, EMD Serono, Genentech, Novartis, Roche, Sanofi Genzyme, and Teva. Dr. Singer has received research support from Barry Singer has received research grant support from AbbVie, Alkermes, MedImmune, Novartis, Roche, and Sanofi Genzyme .
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	058	Safety and Efficacy of Thrombectomy Beyond Traditional Time Window: ‘Real World' Applicability of DAWN trial.	Disclosure: Dr. Patel has nothing to disclose.
Autonomic Manifestations of Disease
Start Time	Pub.	Title	Presenter
11:30 AM	058	Fingolimod does not seem to alter autonomic modulation of bladder in patients with relapsing-remitting multiple sclerosis	Disclosure: Dr. Hilz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme. Dr. Hilz has received personal compensation in an editorial capacity for Autonomic Neuroscience: Basic and Clinical. Dr. Hilz has received research support from Novartis Pharma GmbH.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	058	Efficacy of Tissue Plasminogen Activator (tPA) vs. Aspirin in Patients with a National Institute of Health Stroke Scale (NIHSS) Score Under 5	Disclosure: Dr. Hameed has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	059	Real-World Experience with Ocrelizumab	Disclosure: Dr. Moss has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Genzyme and Roche. Dr. Moss holds stock and For stock options in Pfizer.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	059	Thrombolysis in patients with Down Syndrome and Ischemic Stroke	Disclosure: Dr. Yi has nothing to disclose.
Autonomic Manifestations of Disease
Start Time	Pub.	Title	Presenter
11:30 AM	059	Autonomic Dysfunction in Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Plasma Cell-proliferative Disorder, Skin Changes (POEMS) Syndrome	Disclosure: Dr. Shouman has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	059	Decrease in therapeutic effect among botulinum toxin type A agents: analysis of the FDA adverse event reporting system database	Disclosure: Dr. Kazerooni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merz North America.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	060	Diroximel Fumarate (DRF) in Patients With Relapsing-Remitting Multiple Sclerosis: Interim Efficacy and Safety Results From the Phase 3 EVOLVE-MS-1 Study	Disclosure: Dr. Arnold has nothing to disclose.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	060	“No Touch” Period 24 hours Post TPA Infusion	Disclosure: Dr. Fatima has nothing to disclose.
Autonomic Manifestations of Disease
Start Time	Pub.	Title	Presenter
11:30 AM	060	German Validation of the Composite Autonomic Symptom Score 31	Disclosure: Dr. Wang has nothing to disclose.
General Neurology: Neurotherapeutics, Treatments, and Clinical Trials
Start Time	Pub.	Title	Presenter
11:30 AM	060	Responsiveness of Neuropathy Symptom and Change (NSC) Score Components in Inotersen Treatment of Hereditary Transthyretin Amyloidosis Polyneuropathy	Disclosure: Dr. Dyck has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Ionis.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	061	Cladribine tablets were associated with rapid onset of improvements in MRI outcomes in the ORACLE-MS trial	Disclosure: Dr. Scarberry has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi Genzyme, EMD Serono, & Genentech. Dr. Scarberry has received research support from Biogen, Teva, Mallinckrodt, Sanofi Genzyme, & EMD Serono.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	061	Predictors of Symptomatic Intracerebral Hemorrhage After rtPA	Disclosure: Dr. Nisar has nothing to disclose.
Autonomic Manifestations of Disease
Start Time	Pub.	Title	Presenter
11:30 AM	061	Frequency of Seizures and Epilepsy in Familial Dysautonomia	Disclosure: Dr. Balgobin has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	061	The Impact of Hereditary Transthyretin Amyloidosis (hATTR) on Work: The Patients’ Perspectives	Disclosure: Dr. Raymond has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	062	Lymphopenia rates in CLARITY/CLARITY Extension are consistent in patients with or without high disease activity at baseline	Disclosure: Dr. Cook has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Bayer HealthCare, Sanofi-Aventis, Neurology Reviews, Biogen Idec, Teva Pharmaceuticals, Bayer HealthCare, Merck, Actinobac Biomed, Teva Pharmaceuticals, Biogen Idec and Actinobac Biomed, Inc. Dr. Cook has received research support from Bayer HealthCare.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	062	Prevalence of Multiple Territory Stroke Pattern after Thrombolysis in Patients with or without known Atrial Fibrillation.	Disclosure: Dr. Azeem has nothing to disclose.
Autonomic Manifestations of Disease
Start Time	Pub.	Title	Presenter
11:30 AM	062	Neurogenic bladder dysfunction in patients with familial dysautonomia: a cross-sectional study	Disclosure: Dr. Balgobin has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	062	Quality of Life (QOL) in Patients with Transthyretin Amyloidosis Accompanied by Peripheral Neuropathy (PN)	Disclosure: Dr. Sikora Kessler has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	063	Effect of MD1003 (high dose Pharmaceutical grade Biotin) in the Treatment of Progressive MS: Earlier Treatment Results in Lower Disability Over 48 Months	Disclosure: Dr. De Seze has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi-Genzyme, Teva, Novartis, Roche, Chugai, and Alexion. Dr. De Seze has received research support from Sanofi.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	063	Treatment within the Get with the Guidelines (GWTG) target of less than 45 minutes for intravenous thrombolysis improves 90 day outcome	Disclosure: Dr. Hamdallah has nothing to disclose.
Autonomic Manifestations of Disease
Start Time	Pub.	Title	Presenter
11:30 AM	063	Autonomic Related Gastrointestinal Manifestations of Alternating Hemiplegia of Childhood	Disclosure: Dr. Pratt has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	063	Providing Quality Teleneurology Consults to a State Prison System	Disclosure: Dr. O'Connell has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	064	Effects of Dimethyl Fumarate on Brain Volume Change in Relapsing-remitting Multiple Sclerosis: a Pooled Analysis of the Phase 3 DEFINE and CONFIRM Studies	Disclosure: Dr. Nakamura has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with NeuroRx Research and Sanofi Genzyme. Dr. Nakamura has received royalty, license fees, or contractual rights payments from license fee from Biogen Idec. Dr. Nakamura has received research support from Biogen Idec, Sanofi Genzyme, and Novartis.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	064	No Difference in Door-to-Needle Times by Choice of Antihypertensive Agent Prior to Thrombolysis: A Single Center Experience	Disclosure: Dr. Carrera has nothing to disclose.
Autonomic Manifestations of Disease
Start Time	Pub.	Title	Presenter
11:30 AM	064	Autonomic manifestations before and after renal denervation.	Disclosure: Dr. Gonzalez Duarte has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	064	The Functionality, Evidence and Privacy Issues around Smartphone Apps for the Top Neuropsychiatric Conditions: A Comprehensive Study	Disclosure: Dr. Gopal has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	065	Discontinuation and Comparative Effectiveness of Dimethyl Fumarate and Fingolimod in Two Large Academic Medical Centers at 36-month Follow-Up	Disclosure: Dr. Hersh has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Teva, Genentech, Genzyme, and EMD Serono. Dr. Hersh has received research support from Biogen Idec and Genentech.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	065	IMITA Score: distinguishing between ischemic stroke and stroke mimics	Disclosure: Dr. Rosales has nothing to disclose.
Child Neurology: Neuromuscular Disease: Birth to Adulthood I
Start Time	Pub.	Title	Presenter
11:30 AM	065	Evidence of Decreased Epidermal Neurite Density in Juvenile Fibromyalgia Patients	Disclosure: Dr. Boneparth has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	065	Arts Intervention for Inpatients with Refractory Epilepsy or Migraine: Pilot Feasibility Study	Disclosure: Dr. Ronan has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	066	A Novel Small Molecule Promotor of Remyelination	Disclosure: Dr. Natarajan has nothing to disclose.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	066	Predictors of TC-Perfusion alterations in Stroke-Mimics attended as stroke-code	Disclosure: Dr. Gonzalez-Martinez has nothing to disclose.
Child Neurology: Neuromuscular Disease: Birth to Adulthood I
Start Time	Pub.	Title	Presenter
11:30 AM	066	Characterization of Genetic Neuropathy in Childhood: Single Center Experience.	Disclosure: Dr. Logan has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	066	Residential Medical Intervention Improves Fitness of Patients with Major Depression	Disclosure: Dr. Ramirez has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	067	7-Year Outcomes in MS Patients of African Descent Treated With Alemtuzumab: Follow-up of CARE-MS I and II (TOPAZ study)	Disclosure: Dr. Williams has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Teva Neuroscience, Bayer, Questcor Pharmaceuticals, EMD Serono, Merck KGaA, Pfizer, Novartis, Acorda, and Genzyme.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	067	Louisiana’s Stroke System of Care – Progress in Recanalization Therapy	Disclosure: Dr. Martin-Schild has nothing to disclose.
Child Neurology: Neuromuscular Disease: Birth to Adulthood I
Start Time	Pub.	Title	Presenter
11:30 AM	067	Utility of Electromyography in Neonatal Hypotonia: A Tertiary Center 10-year Experience.	Disclosure: Dr. Guillen has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	067	Comorbidity Burden of Patients with Cluster Headache	Disclosure: Dr. Murinova has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	068	Peginterferon beta-1a every 2 weeks demonstrated better outcomes than glatiramer acetate (GA) once daily in patients with relapsing-remitting multiple sclerosis (RRMS): propensity score matching (PSM) of phase 3 data from ADVANCE and CONFIRM	Disclosure: Dr. Scott has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Sanofi Genzyme, Novartis Pharmaceuticals, and Genentech. Dr. Scott has received research support from Biogen and Genentech.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	068	Louisiana’s Level III Stroke Center Performance Improvement Progress	Disclosure: Dr. Martin-Schild has nothing to disclose.
Child Neurology: Neuromuscular Disease: Birth to Adulthood I
Start Time	Pub.	Title	Presenter
11:30 AM	068	White matter lesions detected by MRI in neonates and children with Congenital Myotonic Dystrophy	Disclosure: Dr. Peglar has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	068	Tale of Caution: Identifying Migrainous Infarction Using Database	Disclosure: Dr. Mannava has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	069	Analysis of disease activity return after natalizumab withdrawal in multiple sclerosis	Disclosure: Dr. Fuentes Rumi has nothing to disclose.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	069	Validation Of Bengali Version Of NIHSS Scale	Disclosure: Dr. Chatterjee has nothing to disclose.
Child Neurology: Neuromuscular Disease: Birth to Adulthood I
Start Time	Pub.	Title	Presenter
11:30 AM	069	Age of Onset, Functional Status, and Quality of Life Outcomes in Patients with Congenital and Childhood-Onset Myotonic Dystrophy Type 1	Disclosure: Ms. Kelder has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	069	Influence Of Early Neurological Complications On Clinical Outcome Following Heart Transplantation.	Disclosure: Dr. Pappolla has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	070	Efficacy of Short Washout Periods After Switching from Natalizumab to an Alternative DMT.	Disclosure: Dr. Hua has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Novartis, EMD Serono, Genentech, Celgene and TG Therapeutics.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	070	Not Making a List: The Agraphic Santa Claus and the Limitations of NIHSS	Disclosure: Dr. Etter has nothing to disclose.
Child Neurology: Neuromuscular Disease: Birth to Adulthood I
Start Time	Pub.	Title	Presenter
11:30 AM	070	Hypotonic Neonate Diagnosed with Congenital Myasthenic Syndrome with Novel Pathogenic Variants in the CHAT Gene	Disclosure: Dr. Sankhla has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	070	The Patient Odyssey to Confirmed Acute Hepatic Porphyria Diagnosis: Neurological Symptoms and Use of Drugs Known to Provoke Porphyria Attacks Prior to Diagnosis	Disclosure: Dr. Pedro has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion Pharmaceuticals, Shire, and Sanofi Genzyme. Dr. Pedro has received research support from Shire, Sanofi Genzyme, Horizon Pharma, and Amicus Therapeutics.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	071	Long-Term Effect of Teriflunomide in Subgroups Defined by Prior Treatment: Pooled Analysis of the Phase 2 Study and Phase 3 TEMSO, TOWER, and TENERE Core and Extension Studies	Disclosure: Dr.Comi has received personal compensation for consulting, serving on a scientific advisory board speaking, or other activities with Sanofi, Genzyme, Novartis, Teva, Merck, Roche, Almirall, Celgene, Forward Pharma, Medday, Excemed.
Emergency Evaluation and Thrombolysis
Start Time	Pub.	Title	Presenter
11:30 AM	071	The Emerging Role of Recombinant Tissue Plasminogen Activator in Improving Neuroplasticity in Patients With Acute Ischemic Stroke	Disclosure: Dr. Soliman has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	071	Recent trends in Guillain-Barré Syndrome related hospitalizations, mortality and resource utilization in United States (2006-2014)	Disclosure: Dr. Kumar has nothing to disclose.
Start Time	Pub.	Title	Presenter
	072	SerumLincLNMAT1Correlated withPhosphorylatedα-SynucleinasSerum Biomarkers of Parkinson’s Disease: A Cross-Sectional Study.	Jing Zou Disclosure: Dr. Zou has nothing to disclose.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	072	Phase 2 AFFINITY Trial Evaluates Opicinumab in a Targeted Population of Patients With Relapsing Multiple Sclerosis: Rationale, Design and Baseline Characteristics	Disclosure: Dr. Zhu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Zhu holds stock and/or stock options in Biogen.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	072	Characteristics of Patients Intubated for Psychogenic Non-epileptic Seizures	Disclosure: Dr. Mayer has nothing to disclose.
Start Time	Pub.	Title	Presenter
	073	Development of an AAV-based microRNA Gene Therapy for Treating Spinocerebellar Ataxia Type 3	Melvin Evers Disclosure: Dr. Evers has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with uniQure. Dr. Evers has received compensation for serving on the Board of Directors of uniQure. Dr. Evers holds stock and/or stock options in uniQure, Inc. which sponsored research in which Dr. Evers was involved as an investigator. Dr. Evers has received research support from uniQure, Inc..
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	073	Peg-Interferon beta 1a induces a sustained and long lasting overexpression of interferon related genes.	Disclosure: Dr. Bertolotto has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck, Novartis, Roche, Sanofi, and Teva.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	073	Positive Signs in Organic Neurological Diseases.	Disclosure: Dr. Aboud has nothing to disclose.
Start Time	Pub.	Title	Presenter
	074	STARS: Results from a safety and efficacy study of OV101 (gaboxadol) in adults and adolescents with Angelman syndrome	Lynne Bird Disclosure: Dr. Bird has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Maximus Federal Services, Inventiv Health, FDNA, and Bionest Consulting. Dr. Bird has received personal compensation in an editorial capacity for Guest Editor for American Journal of Medical Genetics. Dr. Bird has received research support from Ovid Therapeutics.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	074	Number Needed to Treat to Prevent Relapse and Disability Worsening Among Patients with Relapsing MS Treated with Teriflunomide or Cladribine	Disclosure: Dr. Boster has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Idec, Novartis, Sanofi-Genzyme, Genetech, Teva, Medtronic. Dr. Boster has received research support from Biogen Idec, Novartis, Genetech, Actellion, and Sanofi-Genzyme.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	074	Prevalence and Factors Associated with Diabetic Peripheral Neuropathy in Ilorin, North-Central Nigeria.	Disclosure: Dr. Bello has nothing to disclose.
Start Time	Pub.	Title	Presenter
	075	Efficacy, Safety, and Tolerability of Rimegepant 75 mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303	Richard Lipton Disclosure: Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven, which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation, the National Headache Foundation, and Amgen.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	075	Effectiveness and Safety of Fingolimod in Patients Switching from Dimethy Fumarate, Teriflunomide, and Daclizumab in Daily Clinical Routine: Interim Results from PANGAEA 2.0	Disclosure:
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	075	Nonalcoholic Wernicke's Encephalopathy: A Retrospective Study of a Reemerging Neurological Disorder in Kashmir Region of Northern India.	Disclosure: Dr. Shah has nothing to disclose.
Start Time	Pub.	Title	Presenter
	076	Cannabidiol (CBD; 10 and 20mg/kg/day) significantly reduces convulsive seizure frequency in children and adolescents with Dravet syndrome (DS): Results of a dose-ranging, multi-center, randomized, double-blind, placebo-controlled trial (GWPCARE2)	Ian Miller Disclosure: Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Insys pharmaceuticals, GWPharma, TS Alliance, DS Foundation, Visualase, Neuroblate, Zogenix, and Ultragenix. Dr. Miller has received personal compensation in an editorial capacity for Insys pharmaceuticals, GWPharma, TS Alliance, DS Foundation, Visualase, Neuroblate, Zogenix, and Ultragenix. Dr. Miller has received research support from Insys pharmaceuticals, GWPharma, TS Alliance, DS Foundation, Visualase, Neuroblate, Zogenix, and Ultragenix.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	076	Serum Anti-JCV Antibody Status in Western Australian Patients With Multiple Sclerosis	Disclosure: Dr. Pedrini has nothing to disclose.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	076	Demographic and Hemodynamic Characteristics of a large Cohort of Patients with Transient Global Amnesia (TGA)	Disclosure: Dr. Werner has nothing to disclose.
Start Time	Pub.	Title	Presenter
	077	Safety, PK, PD, and exploratory efficacy in single and multiple dose study of a SOD1 antisense oligonucleotide (BIIB067) administered to participants with ALS	Timothy Miller Disclosure: Dr. Miller has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen and Cytokinetics. Dr. Miller has received royalty, license fees, or contractual rights payments from C2N and Ionis Pharmaceuticals. Dr. Miller has received research support from Biogen, Ionis, Orion, and Amylyx.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	077	Quantifying the burden of unfilled clinic appointment slots created by late-notice cancellations	Disclosure: Dr. Wang has nothing to disclose.
Start Time	Pub.	Title	Presenter
	078	Zilucoplan, a Subcutaneously Self-Administered Peptide Inhibitor of Complement Component 5 (C5), for the Treatment of Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial and Open-Label Long-Term Extension	James Howard Disclosure: Dr. Howard has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion Pharmaceuticals. Dr. Howard holds stock and/or stock options in AT&T, General Electric, Pfizer, Johnson & Johnson. Dr. Howard has received research support from Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals, Muscular Dystrophy Association.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	078	Antidrug Antibodies Have Minimal Impact on the Pharmacodynamic Profile and Clinical Efficacy of Alemtuzumab in RRMS Patients From the CARE-MS Studies	Disclosure: Dr. Ziemssen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Fees for participation in scientific advisory boards from Bayer Healthcare, Biogen Idec, Novartis, Merck Serono, Teva, Genzyme, and Synthon; Speaker honorarium from Bayer Healthcare, Biogen, Genzyme, Merck Sharp & Dohme, GlaxoSmithKline, Novartis, Teva, Sanofi, and Almirall. Dr. Ziemssen has received research support from Bayer Healthcare, Biogen, Genzyme, Novartis, Teva, and Sanofi.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	078	Burnout among Japanese Female Neurologists: a Preliminary Investigation	Disclosure: Dr. Aiba has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen Inc., AbbVie GK.
Start Time	Pub.	Title	Presenter
	079	Efficacy and safety of eculizumab in aquaporin-4 antibody positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NMOSD): a phase 3, randomized, double-blind, placebo-controlled, multicenter trial (PREVENT)	Sean Pittock Disclosure: Dr Pittock has provided consultation to Alexion Pharmaceutical and MedImmune but has received no personal fees or compensation for these consulting activities. All compensation for consulting activities is paid directly to Mayo Clinic. Dr. Pittock receives research support from Alexion Pharmaceuticals, Medimmune, and Grifols.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	079	Corticosteroids affect the dynamics of multiple sclerosis lesions formation	Disclosure: Dr. Gaitan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Argentina, Biogen Argentina, and Merck Argentina. Dr. Gaitan has received research support from Novartis Argentina.
General Neurology: Advances in Quality of Care and Wellness
Start Time	Pub.	Title	Presenter
11:30 AM	079	Art Therapy in the Management of Neurology Wellness and Burnout- A Pilot Study	Disclosure: Dr. King has nothing to disclose.
Start Time	Pub.	Title	Presenter
	080	Kelch-like protein 11 autoantibodies are a novel biomarker of testicular cancer-associated paraneoplastic encephalitis	Divyanshu Dubey Disclosure: Dr. Dubey has received research support from Grifols and Center of Multiple Sclerosis and Autoimmune Neurology .
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	080	Long-term Clinical Outcomes in Patients with CIS Treated with Interferon Beta-1b: Clinical and MRI Results from BENEFIT 15	Disclosure: Dr. Kappos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board and consultancy fees from Actelion, Alkermes, Almirall, Bayer, Biogen, Celgene/Receptos, df-mp, Excemed, GeNeuro SA, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Novartis, Roche, sanofi-aventis, Santhera, Teva, Vianex and royalties for Neurostatus-UHB products. . Dr. Kappos has received research support from The Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, the European Union and Roche Research Foundations.
Start Time	Pub.	Title	Presenter
	081	MODULATION OF CSF CASPASE-3 IN MSC-NTF CELLS (NUROWN®) IN A PHASE 2 ALS STUDY: CORRELATIONS WITH CSF BIOMARKERS AND CLINICAL RESPONSE	Ralph Kern Disclosure: Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics.
MS Clinical Trials and Therapeutic Research
Start Time	Pub.	Title	Presenter
11:30 AM	081	Real-world Efficacy of Delayed-Release Dimethyl Fumarate in Early Multiple Sclerosis: Interim Results from ESTEEM	Disclosure: Dr. Giles has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with EMD Serono, Genzyme Corporation, and Biogen Idec.
11:30 AM	082	Sustained improvement in clinical and MRI outcomes in Newly Diagnosed relapsing-remitting multiple sclerosis (RRMS) patients treated for up to 4 years with peginterferon beta-1a: subgroup analysis of ADVANCE/ATTAIN	Disclosure: Dr. Newsome has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Celgene, EMD Serono, Genentech, medDay Pharmaceuticals, and Gerson Lehrman Group.. Dr. Newsome has received research support from Biogen, Genentech, Department of Defense, the National MS Society, and Patient-Centered Outcomes Research Institute.
11:30 AM	083	Biotin in Progressive Multipe Sclerosis in real-life	Disclosure: Dr. Moreau has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Biogen, Merck, Roche, MedDay, Teva, and Sanofi-Genzyme. Dr. Moreau has received research support from Novartis, Biogen, Merck, Roche, MedDay, Teva, and Sanofi-Genzyme.
11:30 AM	084	Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis	Disclosure: Dr. Gold has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Baxter, Bayer Schering, Biogen, CLB Behring, Celgene, Genzyme, Merck Serono, Novartis, Roche, Stendhal, Talecris, and Teva Pharmaceuticals. Dr. Gold has received personal compensation in an editorial capacity for Therapeutic Advances in Neurological Diseases, Experimental Neurology and the Journal of Neuroimmunology. Dr. Gold has received research support from Teva Pharmaceutical Industries Ltd., Biogen Idec, Bayer, Schering Pharma, Genzyme, Merck Serono, and Novartis.
11:30 AM	085	Real life efficacy and tolerability of Teriflunomide: multicentre study in Galicia (TERIGAL 2018).	Disclosure: Dr. Pato has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Novartis, Genzyme, Almirall, Bayern..
11:30 AM	086	PANGAEA: Effectiveness and safety of fingolimod over 5 years in daily clinical practice	Disclosure: Dr. Ziemssen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Fees for participation in scientific advisory boards from Bayer Healthcare, Biogen Idec, Novartis, Merck Serono, Teva, Genzyme, and Synthon; Speaker honorarium from Bayer Healthcare, Biogen, Genzyme, Merck Sharp & Dohme, GlaxoSmithKline, Novartis, Teva, Sanofi, and Almirall. Dr. Ziemssen has received research support from Bayer Healthcare, Biogen, Genzyme, Novartis, Teva, and Sanofi.
11:30 AM	087	Clinical Characteristics and Outcomes Among NARCOMS Registry Participants Treated With Alemtuzumab	Disclosure: Dr. Salter has received personal compensation in an editorial capacity as a statistical consultant for Circulation: Cardiovascular Imaging.
11:30 AM	088	Teriflunomide Use in Participants With Relapsing-Remitting MS Enrolled in the NARCOMS Registry	Disclosure: Dr. Hashemi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sanofi .
11:30 AM	089	Identifying Physiological Predictors of the Solumedrol-Resistant Multiple Sclerosis Relapse and its Clinical Repercussions	Disclosure: Dr. Roy has received personal compensation for consulting serving on a scientific advisory board speaking or other activities with Biogen Teva Mallinkrodt EMD Serono Atara.
11:30 AM	090	Autologous Haematopoetic Stem Cell Transplantation – an Irish Tertiary Referral Centre Experience	Disclosure: Dr. Gaughan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche, Novartis, Abbvie, Biogen. Dr. Gaughan has received research support from Roche via Newman Fellowship, University College Dublin.
11:30 AM	091	Ocrelizumab Treatment Effect on Upper Limb Function in PPMS Patients with Disability: Subgroup Results of the ORATORIO Study to Inform the ORATORIO-HAND Study Design	Disclosure: Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie, Biogen, Novartis, Teva Neuroscience and Roche Diagnostics Corporation. He has also received consultancy fees for advisory board meetings for Merck-Serono, Genzyme-Sanofi, Synthon BV, and Physicians’ Summit and several medical education meetings. Dr. Giovannoni has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders (Elsevier). Dr. Giovannoni has received research support from Takeda Pharmaceutical Company.
11:30 AM	092	Cannabis use by Patients with Multiple Sclerosis in Colorado	Disclosure: Dr. Domen has nothing to disclose.
11:30 AM	093	The Effects of Disease Modifying Therapy on Retinal Structures in Relapsing Remitting Multiple Sclerosis Patients	Disclosure: Dr. Gilroy has nothing to disclose.
11:30 AM	094	Real-World Fingolimod efficacy and safety in Emirati patients with multiple sclerosis	Disclosure: Dr. Ceccarelli has nothing to disclose.
11:30 AM	095	Evaluating the efficacy and safety of 6-week extended interval dosing of natalizumab via a prospective, controlled, randomized, open-label, rater-blinded phase 3b study	Disclosure: Dr. Campbell has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen. Dr. Campbell holds stock and/or stock options in Biogen.
11:30 AM	096	Baseline Characteristics of Patients with Relapsing Multiple Sclerosis in ASCLEPIOS Phase 3 Trials of Ofatumumab Versus Teriflunomide	Disclosure: Dr. Kappos has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board and consultancy fees from Actelion, Alkermes, Almirall, Bayer, Biogen, Celgene/Receptos, df-mp, Excemed, GeNeuro SA, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Novartis, Roche, sanofi-aventis, Santhera, Teva, Vianex and royalties for Neurostatus-UHB products. . Dr. Kappos has received research support from The Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, the European Union and Roche Research Foundations.
11:30 AM	097	Treatment Sequencing and Satisfaction With Alemtuzumab in Relapsing Multiple Sclerosis Patients: Interim Results of the Real-world PRO-ACT Study	Disclosure: Dr. Wray has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alkermes, Bayer, Biogen, EMD Serono, Genentech/Roche, Novartis, Sanofi, Teva, and TG Therapeutics.
11:30 AM	098	Significant and Clinically Meaningful Health-Related Quality of Life Improvements With Alemtuzumab in RRMS Patients in Clinical Practice: Interim Results From a Prospective, Non-Interventional, Real-World Study (PROMiS)	Disclosure: Dr. Khatri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda Therapeutics, Avanir Pharmaceuticals, Bayer, Biogen, EMD Serono, Genentech, Mallinckrodt, Novartis, Sanofi, Terumo BCT, and Teva.
11:30 AM	099	Real-world switching patterns among US generic glatiramer acetate multiple sclerosis patients	Disclosure: Dr. Alexander has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals.
11:30 AM	100	Durability of NEDA-3 status in patients with relapsing multiple sclerosis receiving cladribine tablets: CLARITY Extension	Disclosure: Dr. Giovannoni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AbbVie, Biogen, Novartis, Teva Neuroscience and Roche Diagnostics Corporation. He has also received consultancy fees for advisory board meetings for Merck-Serono, Genzyme-Sanofi, Synthon BV, and Physicians’ Summit and several medical education meetings. Dr. Giovannoni has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders (Elsevier). Dr. Giovannoni has received research support from Takeda Pharmaceutical Company.
11:30 AM	101	The effect of cladribine tablets on delaying the time to conversion to CDMS or McDonald MS is consistent across subgroups in the ORACLE-MS study	Disclosure: Dr. Bowen has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alexion, Alkermes, Amgen, Biogen, Celgene, EMD Serono, Genzyme, Genentech, Novartis, TG Therapeutics, and Teva Neuroscience. Dr. Bowen holds stock and/or stock options in Amgen. Dr. Bowen has received research support from Alkermes, Biogen, Celgene, Genentech, Genzyme, Novartis, Roche, TG Therapeutics.
11:30 AM	102	Gaps in treatment and treatment discontinuation among patients with multiple sclerosis newly-initiating once- or twice-daily oral disease-modifying drugs	Disclosure: Dr. Nicholas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, EMD Serono, Genzyme, Genentech, Novartis, Alexion, and MSAA. Dr. Nicholas has received research support from Biogen, Novartis, and Genzyme.
11:30 AM	103	Characteristics of Patients Switching from Anti-CD20 Therapy to Natalizumab in the Treatment of Multiple Sclerosis.	Disclosure: Dr. Vollmer has nothing to disclose.

Ready to register for the 2019 AAN Annual Meeting?

Related Courses

Saturday, May 4, 2019
7:00 AM-9:00 AM
C1 - What Do I Do Now?: Assessment and Management of Neuropsychiatric Symptoms in Neurocognitive Disorders Daniel Kaufer MD, FAAN
C3 - Clinical EEG: Normal EEG, Normal Variants, and How to Avoid The Common Pitfall of Over-reading Selim Benbadis MD, FAAN
C4 - Pediatric Neuro-ophthalmology Update Christopher Glisson DO, FAAN
C5 - What Do I Do Now?: Neurologic Consultations in Cancer Patients I Jaishri Blakeley MD
C6 - Therapy of Movement Disorders: A Case-based Approach David Riley MD
C7 - Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
C8 - Cognitive Psychology of Neurologic Errors: Why Do Neurologists Make Errors? Louis Caplan MD, FAAN
C2 - Using Sleep Medicine to Help Solve Difficult Neurologic Cases Bradley Vaughn MD, FAAN
8:00 AM-8:30 AM
Are you My Mentor? How to Select a Good Mentor for Your Research Center Deborah Hall MD, PhD, FAAN
9:00 AM-9:30 AM
What Should Applicants Look for in a Program? Adam De Havenon MD
How to Successfully Publish Quality Improvement Projects Anup Patel MD, FAAN
Trainee Experience: Navigating the AAN and Your Career
9:30 AM-11:30 AM
C12 - Clinical Approach to Muscle Disease I: Role of Antibodies, Muscle Imaging, and Genetic Testing Tahseen Mozaffar MD, FAAN
C13 - Clinicopathological Correlation Session in Dementia David Irwin MD
C14 - Child Neurology: Headache Amy Gelfand MD
C15 - Clinical EEG: Focal, Diffuse, and Epileptiform Abnormalities in Adults Katherine Noe MD, PhD, FAAN
C16 - Cerebrovascular Disease I: Prevention Larry Goldstein MD, FAAN, FAHA
C17 - What Do I Do Now?: Neurologic Consultations in Cancer Patients II Patrick Wen MD, FAAN
C18 - Cerebellar and Afferent Ataxias: Diagnosis and Management Massimo Pandolfo MD, FAAN
C19 - Multiple Sclerosis Overview I: Clinical Pearls Mary Willis MD, FAAN
C20 - Neurologic Complications of Medical Disease Sara Hocker MD, FAAN
10:00 AM-10:30 AM
Quality Improvement Research in Neurology Mona Bahouth MD
11:00 AM-11:30 AM
Your CV Is Talking About You Behind Your Back and Your LORs Are, Too! Na Tosha Gatson MD, PhD
11:00 AM-11:45 AM
Fellowship as a Springboard to Junior Faculty Kathryn Nevel MD
12:00 PM-12:30 PM
Navigating the Annual Meeting App Carlayne Jackson MD, FAAN
1:00 PM-1:30 PM
Statistics: Sample Size William Meurer MD
1:00 PM-1:45 PM
Tips and Tools for Successful Recruitment Peggy Nolty
What's Going On With E/M? Luana Ciccarelli , Bruce Cohen MD, FAAN
1:30 PM-3:30 PM
C25 - Clinical Approach to Muscle Disease II: Inflammatory Myopathies and Muscle Pathology Tahseen Mozaffar MD, FAAN
C26 - Clinical EEG: Neonatal and Pediatric Nicholas Abend MD
C27 - Cerebrovascular Disease II: Update on Guidance-Based Diagnosis and Management of Hemorrhagic Stroke Andrew Naidech MD, FAAN
C28 - Sleep-Disordered Breathing in Neurology Populations: From Lab to Clinic Nancy Foldvary-Schaefer DO, FAAN
C34 - Evaluating Tremor in the Office Andres Deik Acosta Madiedo MD
C29 - Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
C30 - Neurologic Complications of Medical and Surgical Therapies Sara Hocker MD, FAAN
C31 - Mitochondrial Disorders in Neurology Michio Hirano MD, FAAN
C32 - The Neurology of Social Behavior Bradford Dickerson MD, FAAN
C33 - Teleneurología (Teleneurology) Susana Bowling MD
1:45 PM-2:30 PM
The Experience of Music Therapy in the Interdisciplinary Treatment of TBI Renee Pazdan MD, FAAN, Rebecca Vaudreuil EdM, MT-BC
2:00 PM-2:45 PM
A Career in Neuroimaging Michael Hutchinson MD, PhD
2:30 PM-3:15 PM
Dancing with Parkinson's Diviya Kaul MD
2:45 PM-3:30 PM
Case Studies: Ethical Conundrums in Neurology Ariane Lewis MD, Winston Chiong MD, Justin Sattin MD, Daniel Larriviere MD, JD, FAAN, William Graf MD, FAAN, James Russell MD, MS, FRPC, FAAN, Salvador Cruz-Flores MD, FAAN
3:00 PM-3:45 PM
Using Technology to Get Real Answers from Your Patients Lidia Maria Moura MD, FAAN
Interventional Neurology: Training and Practice Adnan Qureshi MD
3:00 PM-4:00 PM
AAN Business Meeting
3:45 PM-4:45 PM
Women in Neurology Jennifer Bickel MD, FAAN, Renee Pazdan MD, FAAN, Veronica Santini MD, MA, Meeryo Choe MD
4:15 PM-5:30 PM
Hot Topics Plenary Session Eric Klawiter MD, FAAN
5:00 PM-5:30 PM
Trainee Experience: Navigating the AAN and Your Career
5:00 PM-5:45 PM
Telestroke Across the Continuum Amy Guzik MD
5:45 PM-6:45 PM
Advancing Medicine: Inspiration and Innovation Featuring Hugh Herr, PhD Hugh Herr PhD

Sunday, May 5, 2019
7:00 AM-7:30 AM
Trainee Experience: Navigating the AAN and Your Career
7:00 AM-7:45 AM
Resident Evaluation of Faculty: A New Approach Deborah Fay
7:00 AM-9:00 AM
C46 - Actualización en dolor de cabeza y trastornos neuromusculares (Update: Headache and Neuromuscular Disorder) Jose Merino MD, MPhil, FAAN, Dario Beltran MD, FAAN
C36 - Mastering EMG Waveform Recognition Skills in Just Two Hours! Devon Rubin MD, FAAN
C37 - Chronic Traumatic Encephalopathy: Update Andrew Budson MD
C40 - Child Neurology: Stroke Lori Billinghurst MD
C41 - Neuro-oncology in 2019: Navigating Current Trends Maciej Mrugala MD, PhD, MPH, FAAN
C42 - The Dystonias: Diagnosis, Treatment and Update on Etiologies Rachel Saunders-Pullman MD
C44 - Multiple Sclerosis Therapy: Symptom Management Andrew Solomon MD, FAAN
C45 - Status Epilepticus Stephan Schuele MD, FAAN
8:00 AM-8:30 AM
C260 - Accreditation Step by Step: From Self Study to Site Visit Crys Draconi
Neuroscience of Bias Jose Posas MD
Clerkship Director Conversation Rachel Marie Salas MD, FAAN
8:00 AM-8:45 AM
Coding for Residents Kavit Shah MD
8:30 AM-9:00 AM
C261 - How to Become An Advocate For Yourself and Your Program Sana Ghafoor MD
Neuroscience Course Director Conversation Peter Hannon MD, Madhu Soni MD, FAAN
9:00 AM-10:00 AM
C262 - Choosing, Training, Forging, and Mentoring Chief Residents: Program Coordinator Role Marla Scofield C-TAGME
9:15 AM-12:00 PM
Presidential Plenary Session Natalia Rost MD, MPH, FAAN, FAHA
11:30 AM-6:30 PM
P1 - Poster Session 1
12:00 PM-12:45 PM
Almuerzo con Colegas: Perlas clínicas/ solicitando una residencia o subespecialidad en neurología
12:00 PM-1:00 PM
Neurology Pictionary Bert Vargas MD, FAAN
1:00 PM-2:15 PM
S1 - Neuroepidemiology
1:00 PM-3:00 PM
C60 - Assessment of Rapidly Progressive Dementias I: Prion and Non-prion Neurodegenerative Diseases Michael Geschwind MD, PhD, FAAN
C49 - Neurology Update I: Multiple Sclerosis, Sleep, and Neuromuscular Disease Ralph Jozefowicz MD, FAAN, Adam Quick MD
C50 - Cerebrovascular Disease III: Update on Neuroimaging Modalities and Endovascular Therapies for Acute Ischemic Stroke Johanna Fifi MD, FAAN
C51 - Balance and Gait Disorders Alfonso Fasano MD, PhD
C52 - Introduction to Integrative Neurology Sarah Mulukutla MD, MPH
C53 - Introduction to Primary Headache Disorders: Migraine and Other Primary Headaches Including Tension-Type, Hypnic, Primary Stabbing and Nummular Headache Syndromes, Epicrania Fugax and Retinal Migraine Deborah Friedman MD, MPH, FAAN
C55 - Sleep for the Practicing Neurologist: Is it Narcolepsy or Something Else? Diagnostic and Management Challenges in the Central Disorders of Hypersomnolence Rachel Marie Salas MD, FAAN
C56 - Multiple Sclerosis Therapy: Disease-modifying Treatment I Scott Newsome DO, FAAN
C57 - Drugs and Toxin-induced Neurologic Emergencies Sara Hocker MD, FAAN
C59 - Cuidados Neurocríticos (Neurocritical Care) Susana Bowling MD
C47 - Evaluation and Management of Autonomic Disorders I: Autonomic Testing, Failure, and Peripheral Neuropathies Amanda Peltier MD, MS
S2 - Neurocritical Care
S3 - Epilepsy/Clinical Neurophysiology (EEG) I
S5 - Therapeutics in ALS and SMA
S4 - Clinical Trials in Movement Disorders
S6 - MS and CNS Inflammatory Disease: Clinical Considerations I
1:00 PM-5:30 PM
C64 - Skills Workshop: Neurophysiologic Intraoperative Monitoring (Registration Required) Aatif Husain MD
1:30 PM-2:30 PM
AAN Leadership: Using Experiences to Answer the Tough Questions Ralph Sacco MD, MS, FAHA, FAAN, Sandra Olson MD, FAAN, Roger Rosenberg MD, FAAN, Stanley Fahn MD, FAAN, Robert Griggs MD, FAAN, Terrence Cascino MD, FAAN, Stephen Sergay MB BCh, FAAN, Francis Kittredge MD,FAAN
2:00 PM-2:30 PM
SIGN Faculty Advisor Conversation Yolanda Reyes-Iglesias MD
2:00 PM-2:45 PM
Teaching the Next Generation of Physician Advocates: Advocacy Curriculum for Neurology Residents Jonathan Cahill MD, FAAN, Kara Stavros MD
3:00 PM-3:45 PM
Practice Innovation in Epilepsy Anup Patel MD, FAAN
Lost in Translation: Acknowledging and Respecting Cultural Differences With Your Patients Joseph Sirven MD, FAAN, Jose Merino MD, MPhil, FAAN
Education Research: The Secret Sauce to Career Advancement as Clinician Educator Andrew Southerland MD
3:30 PM-4:45 PM
S8 - Neuro Trauma and Sports Neurology
3:30 PM-5:30 PM
C76 - Assessment of Rapidly Progressive Dementias II: Infections and Autoimmune Mediated Conditions Michael Geschwind MD, PhD, FAAN
C67 - Neurology Update II: Behavioral Neurology, Movement Disorders, and Neuro-ophthalmology Ralph Jozefowicz MD, FAAN, Adam Quick MD
C68 - Cerebrovascular Disease IV: Telestroke Eric Anderson MD, PhD
C69 - The Palliative Care Guide in Neurology: Best Practice in Communication, Advance Care Planning, and End-of-life Care of Patients with Brain Tumors and Other Life-limiting Neurological Disorders Tobias Walbert MD, PhD
C70 - Introduction to Primary Headache Disorders: Trigeminal Autonomic Cephalalgias and Other Primary Headaches Including New Daily Persistent Headache, Cough, Exercise, and Thunderclap Headaches Christopher Boes MD, FAAN
C72 - Disordered Sleep in Common Neurologic Diseases: Traumatic Brain Injury, Stroke, and Parkinson’s Disease LynnMarie Trotti MD
C73 - Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
C74 - CNS Toxicities Neeraj Kumar MD
C65 - Evaluation and Management of Autonomic Disorders II: Diagnostic Approach and Treatments for Dysautonomia Amanda Peltier MD, MS
N1 - Neuroscience in the Clinic: Child Neurology: Emerging Understanding of the Epilepsy-Movement Disorder Spectrum Across the Lifespan Erika Augustine MD, FAAN, Deborah Hall MD, PhD, FAAN
S9 - Aging and Dementia: Clinical Trials and Novel Therapies
S10 - Biomarkers in Movement Disorders
4:00 PM-4:45 PM
Navigating Prior Authorizations Pearce Korb MD, FAAN
4:15 PM-5:00 PM
The Teenage Brain: Neuroscience You Can Use Frances Jensen MD, FAAN
4:45 PM-5:30 PM
Neuro-oncology Section Guided Poster Tour
5:00 PM-5:30 PM
Trainee Experience: Navigating the AAN and Your Career
5:00 PM-5:45 PM
How to Be a Teacher as a Resident Jeremy Cutsforth-Gregory MD
5:15 PM-6:15 PM
Standing on the Shoulders of Giants Cynthia Comella MD, FAAN

Monday, May 6, 2019
7:00 AM-7:30 AM
Tips to Sail Through the IRB Deborah Hall MD, PhD, FAAN
Trainee Experience: Navigating the AAN and Your Career
7:00 AM-8:45 AM
Clerkship Administrators Certification Program Celia Linton
7:00 AM-9:00 AM
C78 - Young Onset and Atypical Alzheimer's Dementia Jonathan Graff-Radford MD
C80 - Epileptologists’ Secrets for the Busy General Neurologist: Localization, Imaging, and Fear of Surgery Carol Ulloa MD
C81 - Core Principles of Brain Tumors Nimish Mohile MD, FAAN
C82 - Stroke in Young Adults and Women Aneesh Singhal MD, FAAN
C83 - Diagnosis and Treatment of Functional Movement Disorders Mark Hallett MD, FAAN
C84 - Approaching the Management of Common Sleep Disorders: Case-based Review for the Non-sleep Specialist Charlene Gamaldo MD, FAAN
C85 - Severe TBI: From ICU to Rehabilitation Susanne Muehlschlegel MD, MPH, FAAN
C86 - Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN
C87 - Skills Workshop: Clinical Usefulness of Botulinum Toxin for Spasticity (Registration Required) Allison Brashear MD, MBA, FAAN
7:30 AM-9:00 AM
Student Interest Group in Neurology (SIGN) Meeting Madhu Soni MD, FAAN
8:00 AM-8:45 AM
Physical Exercise and Cognitive Training in Neurology-Application in Aging & Neurodegenerative Disease Ergun Uc MD
Personal Finances for Residents Brad Klein MD, MBA, FAAN
8:00 AM-9:00 AM
Updating the NIH BRAIN Initiative: A Dialogue with the AAN Walter Koroshetz MD, FAAN
8:30 AM-9:00 AM
Residency Program Director Conversation Rana Said MD, FAAN
9:15 AM-12:00 PM
Contemporary Clinical Issues Plenary Session Randolph Marshall MD, FAAN
11:30 AM-6:30 PM
P2 - Poster Session 2
11:45 AM-12:30 PM
Self-management in Neurologic Disease Lisa Shulman MD, FAAN, Barbara Jobst MD, FAAN
12:00 PM-12:45 PM
Training in Research for Academic Neurologists to Sustain Careers and Enhance the Numbers of Diverse Scholars (TRANSCENDS) Program Bruce Ovbiagele MD, MSc, FAAN
LGBTQ+ Health in Neurology - Why It's Important and What You Need to Know Nicole Rosendale MD
12:00 PM-1:00 PM
Would You Fly With This Pilot? Joseph Sirven MD, FAAN
1:00 PM-1:30 PM
Diversity Officer Roundtable Discussion Roy Hamilton MD, MS, FAAN
1:00 PM-1:45 PM
Controversies in Neuroimaging James Johnston MD, JD, FAAN, James Burke MD
1:00 PM-2:00 PM
Advancing Medicine: Inspiration and Innovation Featuring Mona Hanna-Attisha, MD, MPH, FAAP Mona Hanna-Attisha MD, MPH, FAAP
1:00 PM-3:00 PM
C88 - Mild Cognitive Impairment: Implications for Clinicians Ronald Petersen PhD, MD, FAAN
C101 - Clinical EMG I: Principles and Practice of NCS and Needle EMG Ruple Laughlin MD, FAAN
C90 - Clinical Epilepsy I: Basics Tracey Milligan MD, FAAN
C91 - Neurology Update III: Headache, Neuro-otology, and Epilepsy Ralph Jozefowicz MD, FAAN, Adam Quick MD
C92 - Autism Spectrum Disorders What We Know and Where We Are Going Rujuta Wilson MD
C93 - Paroxysmal Movement Disorders Kailash Bhatia MD, FAAN
C95 - Concussion: Topics in Acute Concussion Nicole Reams MD
C97 - Neuroendocrine Update: Nuts and Bolts of What You Need to Know Alison Pack MD
C100 - Esclerosis Múltiple y Otras Enfermedades Inflamatorias Desmielinizantes y Autoinmunes del Sistema Nervioso Central (MS and Other Demyelinating Inflammatory and Autoimmune Central Nervous System Disorders) Lilyana Amezcua MD, FAAN
N2 - Neuroscience in the Clinic: Interpretations of Genetic Results Massimo Pandolfo MD, FAAN, Karen Marder MD, MPH, FAAN
S12 - Progressive Multiple Sclerosis
S13 - Behavioral and Cognitive Neurology: Behavioral Neurology, Aging, and Dementia
S14 - Translational and Clinical Advances in Neuro-oncology
S15 - Intracerebral Hemorrhage and SAH
S16 - Huntington's Disease: From Bench to Clinical Trials
S17 - Headache: Clinical Trials I
1:00 PM-5:30 PM
C105 - Skills Workshop: Clinical Uses of Botulinum Toxin for Dystonia (Registration Required) Diego Torres-Russotto MD, FAAN
1:30 PM-2:30 PM
Blind Spots: The Impact of Conscious and Unconscious Biases Jeffrey McClean MD, FAAN, Charles Flippen MD, FAAN, Laraine Kaminsky
2:00 PM-2:45 PM
Using EHR to Close Referral Loops Melissa Yu MD, FAAN, Allison Weathers MD, FAAN, Allan Wu MD, FAAN
A Career in Clinical Practice Stephen Sergay MB BCh, FAAN
2:00 PM-3:00 PM
ABPN Continuing Certification Information Session J. Clay Goodman MD, FAAN, A. Gordon Smith MD, FAAN
2:30 PM-3:15 PM
The Role of Integrative Medicine in Epilepsy Ann Marie Collier MD
2:45 PM-3:30 PM
Self Reflected: Deeply Fusing Art and Science to Create the World's Most Complex Artistic Depiction of the Human Brain Greg Dunn PhD
3:00 PM-3:45 PM
Research Outputs from the Axon Registry Lyell Jones MD, FAAN
Child Neurology for Trainees Rana Said MD, FAAN
3:30 PM-4:00 PM
Residency Program Director Conversation Emily Pharr MD
3:30 PM-4:45 PM
S18 - Autonomic Disorders
3:30 PM-5:30 PM
C113 - Concussion: Chronic Symptoms -- Selected Considerations for Why Your Patient May Not be Getting Better Michael Jaffee MD, FAAN
C120 - Clinical EMG II: Case-based Clinical Applications of Nerve Conduction Studies and Needle Electromyography Ruple Laughlin MD, FAAN
C106 - Cognitive Impairment Due to Alzheimer's Disease: Using Old Skills and New Tools for Diagnosis and Treatment David Knopman MD, FAAN
C107 - Emergency Room Neuro-ophthalmology Heather Moss MD, PhD, FAAN
C108 - Clinical Epilepsy II: Considerations Across the Age Span: Pediatrics, Pregnancy, and Elderly Barbara Jobst MD, FAAN
C109 - Neurology Update IV: Stroke, Neuro-infectious Disease, and Autoimmune Encephalopathies Ralph Jozefowicz MD, FAAN, Adam Quick MD
C110 - Adult and Pediatric Neuro-Oncology for the Neurohospitalist Na Tosha Gatson MD, PhD
C111 - Sleep for Resiliency, Recovery and Performance Scott Kutscher MD
C115 - Emerging Approaches to Biosensing for the Diagnosis and Management of Neurological Disease John Hixson MD
C116 - LGBTQI Health in Neurology Holly Hinson MD, MCR, FAAN
C117 - Tourette Syndrome: Assessment and Management Tamara Pringsheim MD, FAAN
C119 - Actualización en lesión cerebral traumática e ictus isquémico (Update: TBI and Stroke) Dario Beltran MD, FAAN, Jose Merino MD, MPhil, FAAN
S19 - Child Neurology: Updates in Autism, Migraine, MS, and Stroke
S20 - Headache Imaging and Physiology and Episodic Syndromes Associated with Migraine
S22 - Stroke Genetics, Cellular Responses, and Animal Models
S23 - Genetic Muscle Disorders
Presentation of the Potamkin Prize for Research in Pick's, Alzheimer's, and Related Diseases
3:45 PM-4:45 PM
Philadelphia: The City of Neurology Love Christopher Goetz MD, FAAN, Stephen Reich MD, FAAN, Frances Jensen MD, FAAN, Donald Silberberg MD,FAAN
4:00 PM-4:30 PM
Clerkship Director Conversation Holli Horak MD, FAAN
4:00 PM-4:45 PM
#MeanReviews: Flipping Imposter Syndrome on Its Head Rachel Marie Salas MD, FAAN
4:30 PM-5:00 PM
Everything You Wanted to Know About the Neurology® Resident & Fellow Section John Millichap MD, FAAN
5:00 PM-5:30 PM
Trainee Experience: Navigating the AAN and Your Career
Residency Program Director Conversation Erica Schuyler MD
Critical Care and Emergency Neurology Section Guided Poster Tour
5:00 PM-5:45 PM
Defining, Evaluating, and Promoting Healthy Cognitive Aging Kirk Daffner MD, FAAN
Careers in Movement Disorders Stanley Fahn MD, FAAN
5:00 PM-6:00 PM
Standing on the Shoulders of Giants Kenneth Heilman MD, FAAN

Tuesday, May 7, 2019
7:00 AM-7:30 AM
Diversifying Your Funding Sources with NIH and Other Sources Ana-Claire Meyer MD
Trainee Experience: Navigating the AAN and Your Career
7:00 AM-7:45 AM
Pursuing a Career in Industry Brandy Matthews MD, FAAN
7:00 AM-9:00 AM
C121 - Clinical EMG III: Nerve Conduction Criteria and Electrodiagnostic Approaches Mark Bromberg MD, PhD, FAAN
C123 - Child Neurology: Genetic and Metabolic Testing in Pediatric Epilepsy James Riviello MD
C122 - Neurocognitive Assessment for Neurologists Mario Mendez MD, PhD, FAAN
C124 - Endovascular Treatment of Acute Stroke and Cerebrovascular Disease Dileep Yavagal MD, FAAN
C125 - Circadian Rhythm Disorders: Implications for Neurology Phyllis Zee MD, PhD
C127 - Hyperkinetic Movement Disorders: Videodiagnosis and Treatment Steven Frucht MD
C129 - Critical Care Consultations for Neurohospitalists Vanja Douglas MD
C130 - Diagnostic Pearls in Myelitis: a Case-based Approach Eoin Flanagan MBBCh
7:30 AM-9:00 AM
C263 - Access: Strategies to Improve Access in Academic Medicine Jaya Trivedi MD, FAAN
8:00 AM-8:45 AM
Welcome to NIH Day/Overview of NIH Funding with NINDS Director and NIA Director, Division of Neuroscience Walter Koroshetz MD, FAAN
9:15 AM-11:30 AM
Clinical Trials Plenary Session Deborah Hall MD, PhD, FAAN, Holly Hinson MD, MCR, FAAN
11:30 AM-6:30 PM
11:45 AM-12:45 PM
Emerging Science Session
12:00 PM-12:30 PM
Learn About Opportunities to Work with the NIH Intramural Program Avindra Nath MD, MBBS, FAAN
12:00 PM-12:45 PM
Optimizing Communication in Difficult Patient Relationships Veronica Santini MD, MA
12:00 PM-1:00 PM
Neuro Game Show: Localize the Lesion Luis Torres MD
12:30 PM-1:00 PM
NIH Grant Review Process Shanta Rajaram PhD
1:00 PM-1:45 PM
Women in Neurology: Thriving Through Challenges Divya Singhal MD, FAAN, Kathrin LaFaver MD, FAAN
K Awards and Training Programs – Planning for a Career as an NIH Investigator Nina Schor MD, PhD, FAAN
1:00 PM-3:00 PM
C132 - Frontotemporal Dementias Elizabeth Finger MD, FAAN
C131 - Small Fiber Neuropathies: Sensory, Autonomic, and Both I: Focus on Autonomic Nervous System Christopher Gibbons MD, FAAN
C133 - Clinical Epilepsy III: Advanced (Status, Beyond AED, Video EEG) William Tatum DO, FAAN
C135 - Case Studies: Challenging Acute Ischemic Stroke Cases Vivien Lee MD, FAAN
C136 - Neuroimaging for the General Neurologist I: Brain Joshua Klein MD, PhD, FANA, FAAN, Ligia Onofrei MD
C137 - Deep Brain Stimulation I: Basic Principles and Programming in Movement Disorders Michael Pourfar MD
C138 - Hot Topics in Headaches and Related Disorders I: Unusual Headaches, Childhood Headaches, and Concussion Management Amy Gelfand MD
C140 - Sports Neurology: Enhancing Athletic Performance Bert Vargas MD, FAAN
C142 - Autoimmune Neurology I Basics and Beyond: Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes of the CNS and PNS Stacey Clardy MD, PhD
N3 - Neuroscience in the Clinic: Stem Cells Antonio Omuro MD, Paul George MD, PhD, MSE
C144 - Actualización científica I (Scientific Update I - Spanish) Edgar Samaniego MD
S25 - Child Neurology: Spinal Muscular Atrophy: Treatments and Outcomes
S26 - MS and CNS Inflammatory Disease: Clinical Considerations II
S27 - General Neurology: Improving Neurologic Care and the Impact of Therapeutics
C264 - Division Chief's Round Table: Maximizing Effectiveness and Addressing Challenges Claire Henchcliffe MD, PhD, FAAN
1:00 PM-5:30 PM
C148 - Skills Workshop: EMG: Basic (Registration Required) Holli Horak MD, FAAN
1:30 PM-2:30 PM
Neuro Exam Tricks and Tips Ludwig Gutmann MD, FAAN, Laurie Gutmann MD, FAAN, Nancy Newman MD, FAAN
1:45 PM-2:15 PM
NIH Funding and Professional Development Opportunities for Diverse Researchers Michelle Jones-London PhD
2:00 PM-2:45 PM
The HSR Game Show Gregory Esper MD, MBA, FAAN, Jason Sico MD, FAAN
2:15 PM-3:00 PM
Clinical Trials and Networks – NeuroNEXT, StrokeNET, SIREN; Alzheimer’s Clinical Trials Consortium Clinton Wright MD, FAAN
3:00 PM-3:45 PM
Live Intraoperative Monitoring Constantine Moschonas MD, FAAN
Oportunidades de colaboración internacional para realizar proyectos de investigación en enfermedades neurodegenerativas (Opportunities for International Collaborations to Conduct Research on Neurodegenerative Diseases) Yakeel Quiroz PhD
AD/ADRD Opportunities Clinton Wright MD, FAAN
3:30 PM-4:00 PM
Writing and Reviewing for the Neurology® Resident & Fellow Section John Millichap MD, FAAN
3:30 PM-5:30 PM
C150 - Small Fiber Neuropathies: Sensory, Autonomic, and Both II: Focus on Sensory Nervous System Christopher Gibbons MD, FAAN
C151 - Lewy Body Dementias Karen Marder MD, MPH, FAAN
C164 - Update on Medical Management of Stroke Adam De Havenon MD
C154 - Neuroimaging for the General Neurologist II: Brain Joshua Klein MD, PhD, FANA, FAAN, Shamik Bhattacharyya MD
C155 - Deep Brain Stimulation II: Advanced Management in Movement Disorders and Applications Beyond Movement Disorders Leonard Verhagen Metman MD, PhD
C156 - Hot Topics in Headaches and Related Disorders II: Migraine Pathophysiology, Brain Imaging, and Therapeutic Advances Andrew Charles MD
C158 - Sports Concussion: Event Coverage Foundational Skills and Sport Specific Pearls Vernon Williams MD, FAAN
C160 - Autoimmune Neurology II Advanced: Autoimmune Encephalitis at the Frontiers of Neuroscience Eoin Flanagan MBBCh
C161 - Child Neurology: Metabolic Marc Patterson MD, FAAN, FRACP
C152 - Clinical Epilepsy IV: Surgery Gregory Cascino MD, FAAN
C163 - Creating a Roadmap for a Diverse Workforce in Academic Neurology Nimish Mohile MD, FAAN, Roy Hamilton MD, MS, FAAN
C149 - Clinical Neurology for Advanced Practice Providers Jessica Erfan PA-C
S30 - Brain Cancer: From Epidemiology to Quality of Life
S31 - MS and CNS Inflammatory Disease: Imaging
S32 - General Neurology: Advances in Neurology: From the Clinic to the Bench
IS2 - Invited Science: Movement Disorders Deborah Hall MD, PhD, FAAN
Presentation of the Sheila Essey Award: An Award for ALS Research
3:45 PM-4:30 PM
HEAL Initiative - Pain Research Funding Opportunities, Clinical and Basic Michael Oshinsky PhD
4:00 PM-4:45 PM
Healthcare Disparities in Populations Jeffrey McClean MD, FAAN, Brett Kissela MD, FAAN, MS, Sharon Lewis MD, Alejandro Vargas MD
Not Dead Yet: How to Remain Relevant and Engaged in Mid to Late Career Heidi Schwarz MD, FAAN
4:30 PM-5:00 PM
Translational Research Amir Tamiz
Using the Neurology® Resident & Fellow Section John Millichap MD, FAAN
5:00 PM-5:30 PM
Trainee Experience: Navigating the AAN and Your Career
5:00 PM-5:45 PM
From Private Practice to Academics Sarah Benish MD, FAAN
5:00 PM-6:00 PM
Standing on the Shoulders of Giants Nancy Newman MD, FAAN

Wednesday, May 8, 2019
7:00 AM-7:30 AM
How to Write and Publish Research Papers, Reviews, and Other Scientific Communication Mark Hallett MD, FAAN
Trainee Experience: Navigating the AAN and Your Career
7:00 AM-7:45 AM
Simulation in Neurology Education Aaron Nelson MD, Arielle Kurzweil MD, Ariane Lewis MD
7:00 AM-9:00 AM
C165 - Current Management of Incidental and Asymptomatic Cerebrovascular Lesions Robert Brown MD, FAAN
C166 - Neuroimaging Biomarkers Across the Dementia Spectrum Liana Apostolova MD, FAAN
C168 - Parkinson's Disease Update Melissa Nirenberg MD, PhD, FAAN
C169 - Neurological Intensive Care I: The Essentials David Greer MD, FAAN
C170 - Video EEG: Name That Spell Amy Crepeau MD
C171 - Child Neurology: Neuromuscular/Autoimmune Neurology Anne Connolly MD, FAAN
C172 - Advances in Neurogenetics Matthew Harms MD
C173 - Skills Workshop: Practical Training in Injection Techniques in the Treatment of Headache Disorders (Registration Required) Amaal Starling MD, Rashmi Halker Singh MD, FAAN
8:00 AM-8:30 AM
Recruiting Underrepresented Populations into Trials Temitayo Oyegbile MD, PhD
8:00 AM-8:45 AM
Complementary Therapies in Parkinson's Disease Veronica Santini MD, MA
Consejos prácticos para educadores médicos (Practical Advice for Medical Educators) Yazmin Odia MD, FAAN, MS
8:30 AM-9:00 AM
Neuroscience Course Director Conversation Madhu Soni MD, FAAN
9:15 AM-11:30 AM
Frontiers in Neuroscience Plenary Session Paul George MD, PhD, MSE
11:00 AM-11:30 AM
Resident and Fellow Conversation Abhimanyu Mahajan MD
11:30 AM-6:30 PM
P4 - Poster Session 4
11:45 AM-12:30 PM
Eating Your Way to Fewer Migraines Belinda Savage-Edwards MD, FAAN, Chef Tess Connor
12:00 PM-12:45 PM
Funding Clinically Oriented/Translational Research Before R01 – Consortium and Foundation Opportunities Aasef Shaikh MD
12:00 PM-1:00 PM
Neuro-Jeopardy: Telencephalon Twisters Laurice Yang MD, MHA, Veronica Santini MD, MA
1:00 PM-1:45 PM
Understanding the AAN's Latest Guidelines Tamara Pringsheim MD, FAAN
Headache Neuromodulation Therapy Heidi Schwarz MD, FAAN
Teaching Neurologic Competency Competently Despite the Competencies: A.B. Baker Award for Lifetime Achievement in Neurologic Education Keynote Address Steven Lewis MD, FAAN
1:00 PM-2:00 PM
Advancing Medicine: Inspiration and Innovation Featuring Patricia Churchland, PhD Patricia Churchland PhD
1:00 PM-3:00 PM
C175 - Neuromuscular Junction Disorders I: Myasthenia Gravis, Ocular, and MuSK Myasthenia Laura Tormoehlen MD, FAAN
C176 - Behavioral Neurology I: Network Anatomy of Behavior and Language Maria Gorno Tempini MD, PhD
C178 - Therapy in Neurology I: Neurological Infectious Diseases and Neuro-oncology Madhu Soni MD, FAAN
C179 - Nonmotor Manifestations of Parkinson's Disease I Jennifer Goldman MD, MS, FAAN
C187 - Comprehensive Migraine Update I: Migraine Diagnosis, Pathophysiology, and Comorbidities Gretchen Tietjen MD
C180 - Neurological Intensive Care II: Acute Brain and Spinal Cord Injury and Acute Neuromuscular Dysfunction Kristine O'Phelan MD
C181 - Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN
C182 - Neuroimaging for the General Neurologist: Spine J. D. Bartleson MD, FAAN, Felix Diehn MD
C185 - Actualización en trastornos del movimiento (Update in Movement Disorders) Andres Deik Acosta Madiedo MD
N4 - Neuroscience in the Clinic: Immunotherapies in Neurological Disease Holly Hinson MD, MCR, FAAN, John Corboy MD, FAAN
S34 - Aging and Dementia: Risk Factors, Biomarkers, and Neuropathology
S35 - Stroke Prevention Strategies
S36 - Epilepsy/Clinical Neurophysiology (EEG) II
S37 - MS Biomarkers
S38 - Headache: Clinical Trials II
1:00 PM-5:30 PM
C190 - Skills Workshop: Neurostimulation (Registration Required) David Spencer MD, FAAN
C191 - Skills Workshop: Neuromuscular Ultrasound (Registration Required) Craig Zaidman MD
1:30 PM-2:30 PM
The Zoo Called - You Have a Consult Ann Tilton MD, FAAN
3:00 PM-3:45 PM
Foundations in Success in the AAN Ann Tilton MD, FAAN, Jeffrey McClean MD, FAAN, Holly Hinson MD, MCR, FAAN, Orly Avitzur MD, MBA, FAAN, Terrence Cascino MD, FAAN, Christine Phelps , Michael Markowski DO, FAAN
How to Successfully Incorporate APPs into Your Practice James Stevens MD, FAAN
3:30 PM-5:30 PM
C192 - Neuromuscular Junction Disorders II: Toxins, Lambert-Eaton Syndrome and Less Common Disorders of Neuromuscular Transmission Laura Tormoehlen MD, FAAN
C193 - Behavioral Neurology II: Memory and Attention Maria Gorno Tempini MD, PhD
C195 - Therapy in Neurology II: Neurocritical Care and Neuromuscular Disease Madhu Soni MD, FAAN
C194 - CANCELED Faculty
C196 - Nonmotor Manifestations of Parkinson's Disease II Jennifer Goldman MD, MS, FAAN
C203 - Comprehensive Migraine Update II: Pharmacologic and Non-Pharmacologic Therapies Gretchen Tietjen MD
C197 - Neurological Intensive Care III: Vascular Diseases Lori Shutter MD, FCCM, FNCS
C198 - Integrating Sleep Medicine Concepts into Your Child Neurology Practice Suresh Kotagal MD, FAAN
C199 - Neuroimaging for the General Neurologist: Peripheral Nerve Kimberly Amrami MD, J. D. Bartleson MD, FAAN
C200 - Neurologic Case Studies in Pregnancy Amy Hessler DO, FAAN
N5 - Neuroscience in the Clinic: Wearable Technology Deborah Hall MD, PhD, FAAN, Eric Klawiter MD, FAAN
S40 - Stroke Risk Factors and Epidemiology
S41 - Imaging in Movement Disorders
S42 - Neuromuscular Disorders
Presentation of the John Dystel Prize for Multiple Sclerosis Research
3:45 PM-4:15 PM
Update on the Complementary Therapies for MS: An Evidence-based Review Vijayshree Yadav MD, FAAN
4:00 PM-4:45 PM
Choosing a Career in Neurocritical Care Katharina Busl MD, MS
4:15 PM-5:00 PM
Is There a Neurologist in the Stands? Javier Cardenas MD, Glynnis Zieman MD
4:45 PM-5:30 PM
Clinical Neurophysiology Section Guided Poster Tour
5:00 PM-5:45 PM
Case Studies: When to Refer Patients for Cognitive Behavioral or Mindfulness-based Psychotherapies: Expanding the Neurologist's Toolkit David Perez MD, Gaston Baslet MD, Aneeta Saxena MD
Perspectivas profesionales para neurólogos en los Estados Unidos y América Latina (Professional Perspectives for Neurologists in the United States and Latin America) Pedro Gonzalez-Alegre MD, Ildefonso Rodriguez-Leyva MD, FAAN
5:15 PM-6:15 PM
Standing on the Shoulders of Giants Vladimir Hachinski MD, DSc, FAAN

Thursday, May 9, 2019
7:00 AM-7:30 AM
So Your Paper Didn’t Get Accepted, Now What? Roy Strowd MD
Trainee Experience: Navigating the AAN and Your Career
7:00 AM-9:00 AM
C205 - Peripheral Neuropathy I: Anatomical Basis and Acquired Demyelinating Neuropathies David Herrmann MD, FAAN
C206 - Vascular Cognitive Impairment and Dementia: Current Status and Future Larry Goldstein MD, FAAN, FAHA
C207 - Emergency Neurology: Evaluation of Coma, Meningitis, and Viral Encephalitis in the Emergency Room Jose Suarez MD, FAAN
C209 - Movement Disorders for the General Neurologist I: New Concepts in the Diagnosis and Management of Parkinson's Disease Irene Litvan MD, FAAN
C210 - Low and High Pressure Headache: Clinical Presentation and Approach to Evaluation and Management Kathleen Digre MD, FAAN
C212 - Principles of Genomic Medicine: Clinical Exome Sequencing in Neurologic Disease Wayne Grody MD, PhD
C214 - Child Neurology: A Case-based Approach Elaine Wirrell MD, FAAN
8:00 AM-8:30 AM
Neuroscience of Bias Jose Posas MD
8:00 AM-8:45 AM
A Migraine in Room 3: Patient-centered Care for Residents Paul Schanfield MD
9:15 AM-11:30 AM
Controversies in Neurology Plenary Session Aleksandar Videnovic MD, MSc, FAAN, Amy Brooks-Kayal MD, FAAN
11:30 AM-6:30 PM
P5 - Poster Session 5
11:45 AM-12:30 PM
How Your Social Life Might Be Helping (or Harming) Your Brain Joel Salinas MD
12:00 PM-12:45 PM
A "How to and Why" of the Shared Medical Appointments: A Way to Meet the Needs of the Patient and Provider While Maximizing Clinical Time Nancy Isenberg MD, MPH, FAAN, Mary Rensel MD, FAAN
12:00 PM-1:00 PM
Who Wants to Be a Millionaire Jose Posas MD
1:00 PM-1:45 PM
Acupuncture Demonstration - 4 Gates Jennifer Bickel MD, FAAN
Are You My Mentor? Finding the Right Fit for Success in Research Holly Hinson MD, MCR, FAAN
1:00 PM-2:30 PM
Preview Film on Robin Williams’ Journey with LBD with His Wife Susan Schneider Williams
1:00 PM-3:00 PM
C215 - Peripheral Neuropathy II: Update on Diabetic, Immune Axonal, and Hematologic-related Neuropathies Michelle Mauermann MD, FAAN
C216 - Higher Cortical Visual Disorders: Case-based Review Sashank Prasad MD
C218 - Critical Care EEG Monitoring Suzette LaRoche MD, FAAN
C219 - Therapy in Neurology III: Epilepsy and Headache David Dodick MD, FAAN
C220 - Movement Disorders for the General Neurologist II: Tremor, Drug-induced Movement Disorders, RLS, and Ataxia Joohi Jimenez Shahed MD
C226 - Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease I Jeffrey Gelfand MD, MAS, FAAN
C221 - Functional Neurologic Disorders I: Movement, Seizures, and Multiple Sclerosis Alberto Espay MD, FAAN
C222 - Good Neurology in Challenging Conditions: Lessons from Military Neurology Michele Gatheridge MD
C223 - United We Stand: Enhancing Your Practice with APPs Jessica Erfan PA-C
C225 - Actualización científica II (Scientific Update II) Alejandro Tobon MD
S46 - Sleep Science and Therapy Updates
S47 - Stroke Outcomes and Recurrence
S48 - Epilepsy/Clinical Neurophysiology (EEG) III
S49 - MS Epidemiology and Risk Stratification
1:00 PM-5:30 PM
C227 - Genomic Neurology: Developing Practical Knowledge of Tools and Concepts Through Case Studies Jeffery Vance MD, PhD
C228 - Skills Workshop: Brain Death: How to Perform a Brain Death Evaluation, Avoid Pitfalls and Convey the News to the Family (Registration Required) Panayiotis Varelas MD, PhD, FAAN
1:30 PM-2:30 PM
Rocky's Legacy: Historical Controversies of Boxing-related Concussions Anthony Alessi MD, FAAN, Barry Jordan MD, Tad Seifert MD
2:00 PM-2:45 PM
Innovative Ways to Decrease Wait Times in Your Practice Jason Sico MD, FAAN
3:00 PM-3:45 PM
How to Navigate the Demands of the First Years of Your Academic Career Nicholas Johnson MD, FAAN
3:00 PM-4:00 PM
Consejos prácticos para un buen examen neurológico (Neuro Exam Tips and Tricks) Jose Biller MD, FAAN, FACP, FAHA
3:30 PM-5:30 PM
C229 - Peripheral Neuropathy III: Genetic Neuropathies: Molecular Diagnosis and Treatment Perspectives Mario Saporta MD, PhD, FAAN
C230 - Disparities in Care Charles Flippen MD, FAAN
C231 - Safe and Appropriate Opioid Prescribing in Neurology Adam Burkey MD
C232 - Women With Epilepsy (WWE): Beyond Seizure Control Anne Van Cott MD, FAAN
C233 - Therapy in Neurology IV: Movement Disorders and Stroke David Dodick MD, FAAN
C234 - Movement Disorders for the General Neurologist III: Chorea, Dystonia, Myoclonus, Stereotypies, and Tics Shyamal Mehta MD, PhD
C236 - Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease II Jeffrey Gelfand MD, MAS, FAAN
C235 - Functional Neurologic Disorders II: Life Experiences and Management of Functional Disorders Alberto Espay MD, FAAN
S51 - Child Neurology: Bench to Bedside: Progress in Treating Genetic Disorders
S52 - Acute Non-Interventional Stroke Care
S53 - Movement Disorders: Genetics and Clinical Features
S54 - Motor Neuron Disease
S55 - MS Basic Science
IS3 - Invited Science: Aging and Dementia Karen Marder MD, MPH, FAAN, Heather Snyder PhD
4:00 PM-4:30 PM
Resident and Fellow Conversation Christopher Perrone MD
4:00 PM-4:45 PM
Neurohospitalist Models of Care in an Academic Department: Opportunities and Challenges S. Josephson MD, FAAN
4:30 PM-5:30 PM
Standing on the Shoulders of Giants Stanley Fahn MD, FAAN
5:00 PM-5:30 PM
Division Chief Conversation Amy Brooks-Kayal MD, FAAN
5:00 PM-5:45 PM
Influence of a Comprehensive Lifestyle Intervention on Prevention of Dementia Dean Sherzai MD, MAS, PhD, Ayesha Sherzai MD
Global Neurology: A Work in Progress Jerome Chin MD, PhD, MPH, FAAN
5:30 PM-6:00 PM
Division Chief Conversation Brenda Banwell MD, FAAN
7:00 PM-10:00 PM
C237 - Case Studies: Diagnosis and Management of Unusual Cases in Neuromuscular Disease Robert Pascuzzi MD, FAAN
C238 - Case Studies in the ICU Katharina Busl MD, MS
C239 - Case Studies: Test Your Knowledge: A Case-based Approach to Neuroimaging Joshua Klein MD, PhD, FANA, FAAN
C240 - Case Studies: Unusual Movement Disorders Kailash Bhatia MD, FAAN
C241 - Case Studies: Challenging Headache Cases Kathleen Digre MD, FAAN
C242 - Case Studies: Dementia Gregory Day MD, MSc

Friday, May 10, 2019
7:00 AM-7:30 AM
Grant Writing 101: Getting Started Logan Schneider MD
Trainee Experience: Navigating the AAN and Your Career
7:00 AM-9:00 AM
C243 - Therapy of Neuromuscular Disease: ALS, Inflammatory Neuropathies and Myopathies, and Myasthenia Gravis Michael Weiss MD, FAAN
C244 - Acute and Chronic Clinical Epilepsy Update Explained in 6 Cases Matthew Hoerth MD
C245 - Controversies in Stroke Treatment and Prevention Pierre Fayad MD, FAAN, FAHA
C246 - Hot Topics and Controversies in Parkinson's Disease Melissa Nirenberg MD, PhD, FAAN
C247 - What Do I Do Now?: Emergency and Inpatient Management of Migraine and Other Headache Disorders Stephanie Nahas MD, FAAN
C248 - Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
C249 - Clinical Pearls: Learning from Complex Cases Simple Lessons that Apply to Everyday Problems S. Josephson MD, FAAN
8:00 AM-8:30 AM
How to Put Together Effective Research Presentations Enrique Leira MD, MS, FAAN
9:15 AM-11:30 AM
Neurology Year in Review Plenary Session Martinson Arnan MD
11:30 AM-1:00 PM
P6 - Poster Session 6
11:45 AM-12:45 PM
Friday Grand Finale: Neuroimaging
12:00 PM-1:00 PM
The Neurology of Creativity at the Keyboard Phillip Pearl MD, FAAN
1:00 PM-1:45 PM
K is for Career Development: Tips on Successful Applications for NIH Career Development Awards Logan Schneider MD
1:00 PM-3:00 PM
C250 - Update in Epilepsy Joseph Sirven MD, FAAN
C252 - Update in Aging and Dementia Gil Rabinovici MD
C253 - Update in Movement Disorders Alfonso Fasano MD, PhD
S56 - MS Trials and Treatment
S57 - Acute Treatment and Imaging of Ischemic Stroke
S58 - Therapeutics in Neuromuscular Disorders
S59 - Migraine: Impact, Treatment Patterns and Resource Utilization
1:30 PM-2:15 PM
Movement Disorder Case Studies: What I Have Learned from My Patients Deborah Hall MD, PhD, FAAN, Susan Fox MD, FAAN
2:00 PM-2:30 PM
Choosing a Career in Neuro-oncology Sylvia Kurz MD, PhD
2:00 PM-2:45 PM
Consensus-based Care Recommendations for Adults with Myotonic Dystrophy Type 1 Nicholas Johnson MD, FAAN
The Sleep Mythbuster!: Illuminating the Facts and Fiction Towards Achieving the Sleep Healthy Neurologist Logan Schneider MD
Consensus-Based Care Recommendations for Adults with haha
2:45 PM-3:30 PM
Neuroanatomy of the Zombie Brain: A Year in Review Brian Hanrahan MD
3:00 PM-3:45 PM
Sleep: Why You Should Spend Your Career Helping People Do It Right Logan Schneider MD
3:30 PM-4:30 PM
C254 - Education Blitz: Child Neurology: Concussion Meeryo Choe MD
C255 - Education Blitz: Normal Pressure Hydrocephalus Neill Graff-Radford MD, FAAN
C257 - Education Blitz: Evolution of Autoimmune Neurology Steven Vernino MD, PhD, FAAN
C258 - Education Blitz: Multiple Sclerosis Stephen Krieger MD, FAAN
C259 - Education Blitz: Sleep Andrew Westwood MD
4:30 PM-5:30 PM
NeuroZone Bert Vargas MD, FAAN, Mark Milstein MD, FAAN, Jennifer Bickel MD, FAAN, Wayne Anderson MD, FAAN

Universal Navigation

P3 - Poster Session 3

Ready to register for the 2019 AAN Annual Meeting?

Related Courses

Footer